

Asia Regional Program

Country Operational Plan

FY 2016



Budget Summary Reports

Summary of Planned Funding by Agency and Funding Source

	Funding Source				Total All	
						Funding
Agency				Funding	Applied	Sources and
Agency	GAP	GHP-State	GHP-USAID	Source Total	Pipeline	Applied
						Pipeline
						Amount
USAID		0	4,453,406	4,453,406	1,780,390	6,233,796
DOD		0		0	71,408	71,408
HHS/CDC	4,116,875	6,007,921		10,124,796	0	10,124,796
HHS/HRSA		100,000		100,000	0	100,000
Total	4,116,875	6,107,921	4,453,406	14,678,202	1,851,798	16,530,000

Summary of Planned Funding by Budget Code and Agency

		Age	ncy		On Hold	
Budget Code	DOD	HHS/CDC	HHS/HRSA	USAID	Amount	Total
НВНС		922,712	50,000	674,073	0	1,646,785
HLAB	0	720,244			0	720,244
HMBL	0				0	0
HTXS		751,599		1,003,303	0	1,754,902
нуст	0	969,813		962,119	0	1,931,932
HVMS	0	2,933,848		507,074	0	3,440,922
HVOP	0	1,084,624	50,000	828,973	0	1,963,597
HVSI	0	1,417,700		31,996	0	1,449,696
НVТВ		115,768			0	115,768
IDUP		5,272			0	5,272
мтст		23,460			0	23,460
OHSS	0	1,065,383		445,868	0	1,511,251
PDCS		70,876			0	70,876
PDTX		43,497			0	43,497

Custom

2017-04-11 10:07 EDT



0 10,124,796 100,000 4,453,406 0 14,678,202		0	10,124,796	100,000	4,453,406	0	
---	--	---	------------	---------	-----------	---	--



Technical Areas

Technical Area Summary

Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
НВНС	1,180,675	0
НУТВ	17,403	0
PDCS	34,881	0
Total Technical Area Planned Funding:	1,232,959	0

Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	322,616	0
HVSI	669,381	0
OHSS	967,629	0
Total Technical Area Planned Funding:	1,959,626	0

Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
HMBL	0	
HVCT	1,369,635	0
HVOP	1,412,816	0
IDUP	0	
МТСТ	5,000	0
Total Technical Area Planned Funding:	2,787,451	0

Technical Area: Treatment

Approved



Budget Code	Budget Code Planned Amount	On Hold Amount
нтхѕ	1,375,085	0
PDTX	22,400	0
Total Technical Area Planned Funding:	1,397,485	0



Technical Area Summary Indicators and Targets

China

Indicator Number	Label	2017
	KP_PREV_TA Percentage of key	
	populations reached with individual	
	and/or small group level HIV	
	preventive interventions that are	n/a
	based on evidence and/or meet the	
	minimum standards required	
	(TA-only)	
	Number of key populations reached	
	with individual and/or small group	
	level HIV preventive interventions	20,371
	that are based on evidence and/or	20,371
	meet the minimum standards	
	required	
	Total estimated number of key	120 571
KP_PREV_TA	population in the catchment area	138,571
	By key population type: Female	
	sex workers (FSW) (Numerator:	
	Number of key populations reached	
	with individual and/or small group	
	level HIV preventive interventions	
	that are based on evidence and/or	
	meet the minimum standards	
	required)	
	By key population type: Males who	
	inject drugs (Male PWID)	
	(Numerator: Number of key	
	populations reached with individual	
	and/or small group level HIV	
	preventive interventions that are	



based on evidence and/or meet the	
minimum standards required)	
By key population type: Females	
who inject drugs (Female PWID)	
(Numerator: Number of key	
populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type: Female	
sex workers (FSW) (Denominator:	
Total estimated number of key	
population in the catchment area)	
By key population type: Males who	
inject drugs (Male PWID)	
(Denominator: Total estimated	
number of key population in the	
catchment area)	
By key population type: Females	
who inject drugs (Female PWID)	
(Denominator: Total estimated	
number of key population in the	
catchment area)	
By key population type: Men who have sex with men and are sex	
workers (Numerator: Number of	
key populations reached with	
individual and/or small group level	
HIV preventive interventions that	
are based on evidence and/or meet	
the minimum standards required)	
By key population type: Men who	
have sex with men and are NOT	20,371
sex workers (Numerator: Number	,
of key populations reached with	



individual and/or small group level	
HIV preventive interventions that	
are based on evidence and/or meet	
the minimum standards required)	
By key population type:	
Transgender who are sex workers	
(Numerator: Number of key	
populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type:	
Transgender who are NOT sex	
workers (Numerator: Number of	
key populations reached with	
individual and/or small group level	
HIV preventive interventions that	
are based on evidence and/or meet	
the minimum standards required)	
By key population type: Men who	
have sex with men and are sex	
workers (Denominator: Total	
estimated number of key	
population in the catchment area)	
By key population type: Men who	
have sex with men and are NOT	
sex workers (Denominator: Total	138,571
estimated number of key	
population in the catchment area)	
By key population type:	
Transgender who are sex workers	
(Denominator: Total estimated	
number of key population in the	
catchment area)	
By key population type:	
-,, population type.	



1		
	Transgender who are NOT sex	
	workers (Denominator: Total	
	estimated number of key	
	population in the catchment area)	
	By key population type: People in	
	prisons and enclosed settings	
	(Numerator: Number of key	
	populations reached with individual	
	and/or small group level HIV	
	preventive interventions that are	
	based on evidence and/or meet the	
	minimum standards required)	
	By key population type: People in	
	prisons and enclosed settings	
	(Denominator: Total estimated	
	number of key population in the	
	catchment area)	
	By Service: KP known positive	
	By Service: KP was tested as part	
	of the program and/or KP was	
	referred for testing as part of the	
	program	
	By New Client Status: New	
	beneficiary	
	By New Client Status: Returning	
	beneficiary within the current report	
	period	
	Number of individuals who received	
	T&C services for HIV and received	4.040
	their test results during the past 12	1,618
	months	
HTC_TST_DSD	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
1	190,007. 20 27 Maie	



Age/sex: 25-49 Male
Age/sex: 50+ Male
Age/sex: 5-9 Female
Age/sex: 10-14 Female
Age/sex: 15-19 Female
Age/sex: 20-24 Female
Age/sex: 25-49 Female
Age/sex: 50+ Female
Test Result by Age and Sex:
Positive: 10-14 Male
Test Result by Age and Sex:
Positive: 15-19 Male
Test Result by Age and Sex:
Positive: 20-24 Male
Test Result by Age and Sex:
Positive: 25-49 Male
Test Result by Age and Sex:
Positive: 50+ Male
Test Result by Age and Sex:
Positive: 10-14 Female
Test Result by Age and Sex:
Positive: 15-19 Female
Test Result by Age and Sex:
Positive: 20-24 Female
Test Result by Age and Sex: Positive: 25-49 Female
Test Result by Age and Sex: Positive: 50+ Female
Test Result by Age and Sex:
Negative: 10-14 Male
Test Result by Age and Sex:
Negative: 15-19 Male
Test Result by Age and Sex:
Negative: 20-24 Male
· •



Test Result by Age and Sex:	
Negative: 25-49 Male	
Test Result by Age and Sex:	
Negative: 50+ Male	
Test Result by Age and Sex:	
Negative: 10-14 Female	
Test Result by Age and Sex:	
Negative: 15-19 Female	
Test Result by Age and Sex:	
Negative: 20-24 Female	
Test Result by Age and Sex:	
Negative: 25-49 Female	
Test Result by Age and Sex:	
Negative: 50+ Female	
Aggregated Age/sex - USE WITH	10
HQ PERMISSION ONLY: <15 Male	18
Aggregated Age/sex - USE WITH	004
HQ PERMISSION ONLY: 15+ Male	834
Aggregated Age/sex - USE WITH	
HQ PERMISSION ONLY: <15	24
Female	
Aggregated Age/sex - USE WITH	
HQ PERMISSION ONLY: 15+	742
Female	
Test Result by Aggregated Age	
and Sex: Negative <15 Male	
Test Result by Aggregated Age	
and Sex: Negative 15+ Male	
Test Result by Aggregated Age	
and Sex: Negative <15 Female	
Test Result by Aggregated Age	
and Sex: Negative 15+ Female	
Test Result by Aggregated Age	0
and Sex: Positive <15 Male	0



Test Result by Aggregated Age and Sex: Positive 15+ Male398Test Result by Aggregated Age and Sex: Positive <15 Female5
and Sex: Positive <15 Female
Test Result by Aggregated Age and Sex: Positive 15+ Female
Test Result by Age: Positive: <1
Test Result by Age: Positive: 1-9
Age/sex: <1
Age/sex: 1-9
Service Delivery Point (Community): Index testing
Service Delivery Point (Community): Homebased testing
Service Delivery Point (Community): Mobile testing
Service Delivery Point (Community): Other
Service Delivery Point (Community) by Age: <15 index testing
Service Delivery Point (Community) by Age: 15+ index testing
Service Delivery Point (Community) by Age: <15 homebased testing
Service Delivery Point (Community) by Age: 15+ homebased testing
Service Delivery Point (Community) by Age: <15 mobile testing
Service Delivery Point (Community) by Age: 15+ mobile testing
Service Delivery Point (Community) by Age: <15 other
Service Delivery Point (Community) by Age: <15 other



Service Delivery Point (Facility):	
Inpatient	
Service Delivery Point (Facility): Outpatient	
Service Delivery Point (Facility): Pediatric	
Service Delivery Point (Facility): Malnutrition facilities	
Service Delivery Point (Facility): Other PITC	
Service Delivery Point (Facility): VCT	35
Service Delivery Point (Facility): VMMC	
Service Delivery Point (Facility): PMTCT	
Service Delivery Point (Facility): TB Clinics	
Service Delivery Point (Facility): Index testing	15
Service Delivery Point (Facility) by Age: <15 Inpatient	
Service Delivery Point (Facility) by Age: >15 Inpatient	
Service Delivery Point (Facility) by Age: <15 Outpatient	
Service Delivery Point (Facility) by Age: >15 Outpatient	
Service Delivery Point (Facility) by Age: <15 Pediatroc	
Service Delivery Point (Facility) by Age: >15 Pediatroc	
Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	



	Service Delivery Point (Facility) by	
	Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by	
	Age: <15 Other PITC	
	Service Delivery Point (Facility) by	
	Age: >15 Other PITC	
	Service Delivery Point (Facility) by	
	Age: <15 VCT	
	Service Delivery Point (Facility) by	
	Age: >15 VCT	
	Service Delivery Point (Facility) by	
	Age: <15 VMMC	
	Service Delivery Point (Facility) by	
	Age: >15 VMMC	
	Service Delivery Point (Facility) by	
	Age: <15 PMTCT	
	Service Delivery Point (Facility) by	
	Age: >15 PMTCT	
	Service Delivery Point (Facility) by	
	Age: <15 TB Clinics	
	Service Delivery Point (Facility) by	
	Age: >15 TB Clinics	
	Service Delivery Point (Facility) by	
	Age: <15 Index testing	
	Service Delivery Point (Facility) by	
	Age: >15 Index testing	
	Number of individuals who received	
	T&C services for HIV and received	11,900
	their test results during the past 12	· · ;
HTC_TST_TA	months	
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	



Age/sex: 25-49 Male
Age/sex: 50+ Male
Age/sex: 5-9 Female
Age/sex: 10-14 Female
Age/sex: 15-19 Female
Age/sex: 20-24 Female
Age/sex: 25-49 Female
Age/sex: 50+ Female
Test Result by Age and Sex:
Positive: 10-14 Male
Test Result by Age and Sex:
Positive: 15-19 Male
Test Result by Age and Sex:
Positive: 20-24 Male
Test Result by Age and Sex:
Positive: 25-49 Male
Test Result by Age and Sex:
Positive: 50+ Male
Test Result by Age and Sex:
Positive: 10-14 Female
Test Result by Age and Sex:
Positive: 15-19 Female
Test Result by Age and Sex:
Positive: 20-24 Female
Test Result by Age and Sex: Positive: 25-49 Female
Test Result by Age and Sex: Positive: 50+ Female
Test Result by Age and Sex:
Negative: 10-14 Male
Test Result by Age and Sex:
Negative: 15-19 Male
Test Result by Age and Sex:
Negative: 20-24 Male
· I



Test Result by Age and Sex:
Negative: 25-49 Male
Test Result by Age and Sex:
Negative: 50+ Male
Test Result by Age and Sex:
Negative: <1 Female
Test Result by Age and Sex:
Negative: 10-14 Female
Test Result by Age and Sex:
Negative: 15-19 Female
Test Result by Age and Sex:
Negative: 20-24 Female
Test Result by Age and Sex:
Negative: 25-49 Female
Test Result by Age and Sex:
Negative: 50+ Female
Aggregated Age/sex - USE WITH
HQ PERMISSION ONLY: <15 Male
Aggregated Age/sex - USE WITH
HQ PERMISSION ONLY: 15+ Male
Aggregated Age/sex - USE WITH
HQ PERMISSION ONLY: <15
Aggregated Age/sex - USE WITH
HQ PERMISSION ONLY: 15+
Female
Test Result by Aggregated Age
and Sex: Negative <15 Male
Test Result by Aggregated Age
and Sex: Negative 15+ Male
Test Result by Aggregated Age
and Sex: Negative <15 Female
Test Result by Aggregated Age
and Sex: Negative 15+ Female



Test Result by Aggregated Age and Sex: Positive <15 Male Test Result by Aggregated Age and Sex: Positive 15+ Male Test Result by Aggregated Age and Sex: Positive <15 Female Test Result by Aggregated Age and Sex: Positive <15 Female Test Result by Aggregated Age and Sex: Positive 15+ Female Test Result by Agg: Positive: <1 Test Result by Agg: Positive: <1 Age/sex: <1 Age/sex: <1 Age/sex: <1 Service Delivery Point (Community): Index testing Service Delivery Point (Community): Homebased testing Service Delivery Point (Community): Mobile testing Service Delivery Point (Community): Other Service Delivery Point (Community): Other Service Delivery Point (Community) by Age: <15 index testing Service Delivery Point (Community) by Age: <15 index testing Service Delivery Point (Community) by Age: <15 index testing Service Delivery Point (Community) by Age: <15 index testing Service Delivery		
Test Result by Aggregated Age and Sex: Positive 15+ Male962Test Result by Aggregated Age and Sex: Positive <15 Female	Test Result by Aggregated Age	
and Sex: Positive 15+ Male 962 Test Result by Aggregated Age and Sex: Positive <15 Female	and Sex: Positive <15 Male	
and Sex: Positive 15+ Male Test Result by Aggregated Age and Sex: Positive <15 Female Test Result by Aggregated Age and Sex: Positive 15+ Female Test Result by Age: Positive: <1 Test Result by Age: Positive: <1 Test Result by Age: Positive: <1 Age/sex: <1 Age/sex: <1 Age/sex: <1 Service Delivery Point (Community): Index testing Service Delivery Point (Community): Nobile testing Service Delivery Point (Community): Nobile testing Service Delivery Point (Community): Other Service Delivery Point (Community): Dy Age: <15 index testing Service Delivery Point (Community) by Age: <15 homebased testing Service Delivery Point (Community) by Age: <15 homebased testing Service Delivery Point (Community) by Age: <15 homebased testing Service Delivery Point (Community) by Age: <15 homebased testing Service Delivery Point (Community) by Age: <15 homebased testing Service Delivery Point (Community) by Age: <15 homebased testing Service Delivery Point (Community) by Age: <15 homebased testing Service Delivery Point (Community) by Age: <15 homebased testing Service Delivery Point (Community) by Age: <15 homebased testing Service Delivery Point (Community) by Age: <15 homebased testing Service Delivery Point (Community) by Age: <15 homebased testing Service Delivery Point (Community) by Age: <15 homebased testing Service Delivery Point (Community) by Age: <15 homebased testing Service Delivery Point (Community) by Age: <15 homebased testing Service Delivery Point (Community) by Age: <15 homebased testing Service Delivery Point (Community) by Age: <15 homebased testing Service Delivery Point (Community) by Age: <15 homebased testing Service Delivery Point (Community) by Age: <15 homebased testing Service Delivery Point (Community) by Age: <15 homebased testing Service Delivery Point (Community) by Age: <15 homebased testing Service Delivery Point (Community) by Age: <15 homebased testing Service Delivery Po	Test Result by Aggregated Age	062
and Sex: Positive <15 Female Test Result by Aggregated Age and Sex: Positive 15+ Female Test Result by Age: Positive: <1 Test Result by Age: Positive: <1 Test Result by Age: Positive: 1-9 Age/sex: <1 Age/sex: <1 Age/sex: <1 (Community): Index testing Service Delivery Point (Community): Homebased testing Service Delivery Point (Community): Mobile testing Service Delivery Point (Community): Other Service Delivery Point (Community): Other Service Delivery Point (Community) by Age: <15 homebased testing Service Delivery Point (Community) by Age: <15 homebased testing Service Delivery Point (Community) by Age: <15 homebased testing Service Delivery Point (Community) by Age: <15 homebased testing Service Delivery Point (Community) by Age: <15 homebased testing Service Delivery Point (Community) by Age: <15 homebased testing Service Delivery Point (Community) by Age: <15 homebased testing Service Delivery Point (Community) by Age: <15 homebased testing Service Delivery Point (Community) by Age: <15 homebased testing Service Delivery Point (Community) by Age: <15 homebased testing Service Delivery Point (Community) by Age: <15 homebased testing Service Delivery Point (Community) by Age: <15 homebased testing Service Delivery Point (Community) by Age: <15 homebased testing Service Delivery Point (Community) by Age: <15 homebased testing Service Delivery Point (Community) by Age: <15 homebased testing Service Delivery Point (Community) by Age: <15 homebased testing Service Delivery Point (Community) by Age: <15 homebased testing Service Delivery Point (Community) by Age: <15 homebased testing Service Delivery Point (Community) by Age: <15 homebased testing Service Delivery Point (Community) by Age: <15 homebased testing Service Delivery Point (Community) by Age: <15 homebased testing Service Delivery Point (Community) by Age: <15 homebased testing Service Delivery Point (Community) by Age: <15 homebased testing Service Delivery Point (Community) by Age: <15 homebased testing Service Delivery Point (Community) by Age: <15	and Sex: Positive 15+ Male	902
Test Result by Aggregated Age and Sex: Positive 15+ FemaleTest Result by Age: Positive: <1	Test Result by Aggregated Age	
and Sex: Positive 15+ FemaleTest Result by Age: Positive: <1	and Sex: Positive <15 Female	
Test Result by Age: Positive: <1Test Result by Age: Positive: 1-9Age/sex: <1	Test Result by Aggregated Age	
Test Result by Age: Positive: 1-9Age/sex: <1	and Sex: Positive 15+ Female	
Age/sex: <1Age/sex: 1-9Service Delivery Point11,900(Community): Index testing11,900Service Delivery Point(Community): Homebased testingService Delivery Point(Community): Mobile testingService Delivery Point(Community): Mobile testingService Delivery Point(Community): OtherService Delivery Point (Community)by Age: <15 index testing	Test Result by Age: Positive: <1	
Age/sex: 1-9 Service Delivery Point (Community): Index testing Service Delivery Point (Community): Homebased testing Service Delivery Point (Community): Homebased testing Service Delivery Point (Community): Mobile testing Service Delivery Point (Community): Mobile testing Service Delivery Point (Community): Other Service Delivery Point (Community) by Age: <15 index testing	Test Result by Age: Positive: 1-9	
Service Delivery Point (Community): Index testing Service Delivery Point (Community): Homebased testing Service Delivery Point (Community): Mobile testing Service Delivery Point (Community): Other Service Delivery Point (Community) by Age: <15 index testing Service Delivery Point (Community) by Age: 15+ index testing Service Delivery Point (Community) by Age: <15 homebased testing Service Delivery Point (Community) by Age: <15 homebased testing Service Delivery Point (Community) by Age: <15 homebased testing Service Delivery Point (Community) by Age: <15 mobile testing Service Delivery Point (Community)	Age/sex: <1	
(Community): Index testing11,900Service Delivery Point(Community): Homebased testingService Delivery Point(Community): Mobile testingService Delivery Point(Community): OtherService Delivery Point (Community)by Age: <15 index testing	Age/sex: 1-9	
(Community): Index testing Service Delivery Point (Community): Homebased testing Service Delivery Point (Community): Mobile testing Service Delivery Point (Community): Other Service Delivery Point (Community) by Age: <15 index testing	Service Delivery Point	
(Community): Homebased testingService Delivery Point(Community): Mobile testingService Delivery Point(Community): OtherService Delivery Point (Community)by Age: <15 index testing	(Community): Index testing	11,900
Service Delivery Point (Community): Mobile testing Service Delivery Point (Community): Other Service Delivery Point (Community) by Age: <15 index testing Service Delivery Point (Community) by Age: 15+ index testing Service Delivery Point (Community) by Age: <15 homebased testing Service Delivery Point (Community) by Age: 15+ homebased testing Service Delivery Point (Community) by Age: <15 mobile testing Service Delivery Point (Community) by Age: <15 mobile testing Service Delivery Point (Community) by Age: 15+ mobile testing Service Delivery Point (Community) by Age: 15+ mobile testing Service Delivery Point (Community)	Service Delivery Point	
(Community): Mobile testingService Delivery Point(Community): OtherService Delivery Point (Community)by Age: <15 index testing	(Community): Homebased testing	
Service Delivery Point (Community): Other Service Delivery Point (Community) by Age: <15 index testing Service Delivery Point (Community) by Age: 15+ index testing Service Delivery Point (Community) by Age: <15 homebased testing Service Delivery Point (Community) by Age: 15+ homebased testing Service Delivery Point (Community) by Age: <15 mobile testing Service Delivery Point (Community) by Age: <15 mobile testing Service Delivery Point (Community) by Age: 15+ mobile testing Service Delivery Point (Community) by Age: 15+ mobile testing	Service Delivery Point	
(Community): OtherService Delivery Point (Community)by Age: <15 index testing	(Community): Mobile testing	
Service Delivery Point (Community) by Age: <15 index testing Service Delivery Point (Community) by Age: 15+ index testing Service Delivery Point (Community) by Age: <15 homebased testing Service Delivery Point (Community) by Age: 15+ homebased testing Service Delivery Point (Community) by Age: <15 mobile testing Service Delivery Point (Community) by Age: <15 mobile testing Service Delivery Point (Community) by Age: 15+ mobile testing Service Delivery Point (Community) by Age: 15+ mobile testing	Service Delivery Point	
by Age: <15 index testing Service Delivery Point (Community) by Age: 15+ index testing Service Delivery Point (Community) by Age: <15 homebased testing Service Delivery Point (Community) by Age: 15+ homebased testing Service Delivery Point (Community) by Age: <15 mobile testing Service Delivery Point (Community) by Age: 15+ mobile testing Service Delivery Point (Community) by Age: 15+ mobile testing Service Delivery Point (Community)	(Community): Other	
Service Delivery Point (Community) by Age: 15+ index testing Service Delivery Point (Community) by Age: <15 homebased testing Service Delivery Point (Community) by Age: 15+ homebased testing Service Delivery Point (Community) by Age: <15 mobile testing Service Delivery Point (Community) by Age: 15+ mobile testing Service Delivery Point (Community) by Age: 15+ mobile testing	Service Delivery Point (Community)	
by Age: 15+ index testing Service Delivery Point (Community) by Age: <15 homebased testing Service Delivery Point (Community) by Age: 15+ homebased testing Service Delivery Point (Community) by Age: <15 mobile testing Service Delivery Point (Community) by Age: 15+ mobile testing Service Delivery Point (Community) by Age: 15+ mobile testing	by Age: <15 index testing	
Service Delivery Point (Community) by Age: <15 homebased testing Service Delivery Point (Community) by Age: 15+ homebased testing Service Delivery Point (Community) by Age: <15 mobile testing Service Delivery Point (Community) by Age: 15+ mobile testing Service Delivery Point (Community)	Service Delivery Point (Community)	
by Age: <15 homebased testing Service Delivery Point (Community) by Age: 15+ homebased testing Service Delivery Point (Community) by Age: <15 mobile testing Service Delivery Point (Community) by Age: 15+ mobile testing Service Delivery Point (Community)	by Age: 15+ index testing	
Service Delivery Point (Community) by Age: 15+ homebased testing Service Delivery Point (Community) by Age: <15 mobile testing Service Delivery Point (Community) by Age: 15+ mobile testing Service Delivery Point (Community)	Service Delivery Point (Community)	
by Age: 15+ homebased testing Service Delivery Point (Community) by Age: <15 mobile testing Service Delivery Point (Community) by Age: 15+ mobile testing Service Delivery Point (Community)	by Age: <15 homebased testing	
Service Delivery Point (Community) by Age: <15 mobile testing Service Delivery Point (Community) by Age: 15+ mobile testing Service Delivery Point (Community)	Service Delivery Point (Community)	
by Age: <15 mobile testing Service Delivery Point (Community) by Age: 15+ mobile testing Service Delivery Point (Community)	by Age: 15+ homebased testing	
Service Delivery Point (Community) by Age: 15+ mobile testing Service Delivery Point (Community)	Service Delivery Point (Community)	
by Age: 15+ mobile testing Service Delivery Point (Community)	by Age: <15 mobile testing	
Service Delivery Point (Community)	Service Delivery Point (Community)	
	by Age: 15+ mobile testing	
by Age: <15 other	Service Delivery Point (Community)	
	 by Age: <15 other	



Service Delivery Point (Community)
by Age: <15 other
Service Delivery Point (Facility):
Inpatient
Service Delivery Point (Facility):
Outpatient
Service Delivery Point (Facility):
Pediatric
Service Delivery Point (Facility):
Malnutrition facilities
Service Delivery Point (Facility):
Other PITC
Service Delivery Point (Facility):
VCT
Service Delivery Point (Facility):
VMMC
Service Delivery Point (Facility):
РМТСТ
Service Delivery Point (Facility): TB
Clinics
Service Delivery Point (Facility):
Index testing
Service Delivery Point (Facility) by
Age: <15 Inpatient
Service Delivery Point (Facility) by
Age: >15 Inpatient
Service Delivery Point (Facility) by
Age: <15 Outpatient
Service Delivery Point (Facility) by
Age: >15 Outpatient
Service Delivery Point (Facility) by
Age: <15 Pediatroc
6
Service Delivery Point (Facility) by
Age: >15 Pediatroc



	Service Delivery Point (Facility) by	
	Age: <15 Malnutrition facilities	
	Service Delivery Point (Facility) by	
	Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by	
	Age: <15 Other PITC	
	Service Delivery Point (Facility) by	
	Age: >15 Other PITC	
	Service Delivery Point (Facility) by	
	Age: <15 VCT	
	Service Delivery Point (Facility) by	
	Age: >15 VCT	
	Service Delivery Point (Facility) by	
	Age: <15 VMMC	
	Service Delivery Point (Facility) by	
	Age: >15 VMMC	
	Service Delivery Point (Facility) by	
	Age: <15 PMTCT	
	Service Delivery Point (Facility) by	
	Age: >15 PMTCT	
	Service Delivery Point (Facility) by	
	Age: <15 TB Clinics	
	Service Delivery Point (Facility) by	
	Age: >15 TB Clinics	
	Service Delivery Point (Facility) by	
	Age: <15 Index testing	
	Service Delivery Point (Facility) by	
	Age: >15 Index testing	
	Number of adults and children	
	receiving antiretroviral therapy	390
TX_CURR_DSD	(ART)	
	Age/Sex: 15-19 Male	
	Age/Sex: 15-19 Female	
	Age/Sex: 20+ Female	



	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	1
	Aggregated Age/Sex: 15+ Male	219
	Aggregated Age/Sex: <15 Female	0
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	170
	Sum of Aggregated Age/Sex <15	1
	Sum of Aggregated Age/Sex 15+	389
	Sum of Aggregated Age/Sex disaggregates	390
	Age/Sex: <1	
	Age/Sex: <1-9	
	Age/Sex: 10-14 Male	
	Age/Sex: 10-14 Female	
	Aggregated Age/Sex: 1-14 Male	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
1	Age/Sex: 50+ Female	
	Number of adults and children newly enrolled on antiretroviral therapy (ART)	60
	By Age/Sex: <1	
TX_NEW_DSD	By Age/Sex: 1-9	
	By Age/Sex: 10-14 Male	
	By Age/Sex: 15-19 Male	
	By Age/Sex: 20-24 Male	



	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	
	By Age/Sex: 20-24 Female	
	By Age/Sex: 25-49 Female	
	By Age/Sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	0
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	42
	Aggregated Grouping by Age/Sex: <pre><1 Female</pre>	
	Aggregated Grouping by Age/Sex: <pre><15 Female</pre>	0
	Aggregated Grouping by Age/Sex: 15+ Female	18
	Sum of Aggregated Age/Sex disaggregates	60
	Pregnancy status	
	Breastfeeding status	
	Aggregated Grouping by Age/Sex: 1-14 Female	
TX_PVLS_DSD	TX_PVLS_DSD Percentage of ART patients with a viral load result documented in the medical record	n/a
	and/or laboratory information systems (LIS) within the past 12	



months with a suppressed viral	
load (<1000 copies/ml)	
Number of adults and pediatric	
patients on ART with suppressed	
viral load results (<1,000 copies/ml)	268
documented in the medical records	200
and /or supporting laboratory	
results within the past 12 months.	
Number of adult and pediatric ART	
patients with a viral load result	
documented in the patient medical	287
record and /or laboratory records	
in the past 12 months.	
Numerator: Indication: Routine	268
Numerator: Indication: Targeted	0
Numerator: Preg/BF by Indication:	
Pregnant Routine	
Numerator: Preg/BF by Indication:	
Breastfeeding Routine	
Numerator: Preg/BF by Indication:	
Pregnant Targeted	
Numerator: Preg/BF by Indication:	
Breastfeeding Targeted	
Numerator: Age/Sex by Indication:	
<1 Routine	
Numerator: Age/Sex by Indication:	
1-9 Routine	
Numerator: Age/Sex by Indication:	
10-14 Male Routine	
Numerator: Age/Sex by Indication:	
15-19 Male Routine	
Numerator: Age/Sex by Indication:	
20-24 Male Routine	
Numerator: Age/Sex by Indication:	



25-49 Male Routine
Numerator: Age/Sex by Indication:
50+ Male Routine
Numerator: Age/Sex by Indication:
10-14 Female Routine
Numerator: Age/Sex by Indication:
15-19 Female Routine
Numerator: Age/Sex by Indication:
20-24 Female Routine
Numerator: Age/Sex by Indication:
25-49 Female Routine
Numerator: Age/Sex by Indication:
50+ Female Routine
Numerator: Age/Sex by Indication:
<1 Targeted
Numerator: Age/Sex by Indication:
1-9 Targeted
Numerator: Age/Sex by Indication:
10-14 Male Targeted
Numerator: Age/Sex by Indication:
15-19 Male Targeted
Numerator: Age/Sex by Indication:
20-24 Male Targeted
Numerator: Age/Sex by Indication:
25-49 Male Targeted
Numerator: Age/Sex by Indication: 50+ Male Targeted
Numerator: Age/Sex by Indication:
10-14 Female Targeted
Numerator: Age/Sex by Indication:
15-19 Female Targeted
Numerator: Age/Sex by Indication:
20-24 Female Targeted
Numerator: Age/Sex by Indication:



25-49 Female Targeted	
Numerator: Age/Sex by Indication:	
50+ Female Targeted	
Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	
Numerator: Aggregate Age/Sex by	
Indication: 15+ Male Targeted	
Numerator: Aggregate Age/Sex by	
Indication: <15 Female Targeted	
Numerator: Aggregate Age/Sex by	
Indication: 15+ Female Targeted	
Numerator: Aggregate Age/Sex by	
Indication: <15 Male Routine	
Numerator: Aggregate Age/Sex by	
Indication: 15+ Male Routine	
Numerator: Aggregate Age/Sex by	
Indication: <15 Female Routine	
Numerator: Aggregate Age/Sex by	
Indication: 15+ Female Routine	
Denominator: Indication: Routine	287
Denominator: Indication: Targeted	0
Denominator: Preg/BF by	
Indication: Pregnant Routine	
Denominator: Preg/BF by	
Indication: Breastfeeding Routine	
Denominator: Preg/BF by	
Indication: Pregnant Targeted	
Denominator: Preg/BF by	
Indication: Breastfeeding Targeted	
Denominator: Age/Sex by	
Indication: <1 Routine	
Denominator: Age/Sex by	
Indication: 1-9 Routine	
Denominator: Age/Sex by	
÷ ,	



Indication: 10-14 Male Routine
Denominator: Age/Sex by
Indication: 15-19 Male Routine
Denominator: Age/Sex by
Indication: 20-24 Male Routine
Denominator: Age/Sex by
Indication: 25-49 Male Routine
Denominator: Age/Sex by
Indication: 50+ Male Routine
Denominator: Age/Sex by
Indication: 10-14 Female Routine
Denominator: Age/Sex by
Indication: 15-19 Female Routine
Denominator: Age/Sex by
Indication: 20-24 Female Routine
Denominator: Age/Sex by
Indication: 25-49 Female Routine
Denominator: Age/Sex by
Indication: 50+ Female Routine
Denominator: Age/Sex by
Indication: <1 Targeted
Denominator: Age/Sex by
Indication: 1-9 Targeted
Denominator: Age/Sex by
Indication: 10-14 Male Targeted
Denominator: Age/Sex by
Indication: 15-19 Male Targeted
Denominator: Age/Sex by
Indication: 20-24 Male Targeted
Denominator: Age/Sex by
Indication: 25-49 Male Targeted
Denominator: Age/Sex by
Indication: 50+ Male Targeted
Denominator: Age/Sex by



1	
Indication: 10-14 Female Targeted	
Denominator: Age/Sex by	
Indication: 15-19 Female Targeted	
Denominator: Age/Sex by	
Indication: 20-24 Female Targeted	
Denominator: Age/Sex by	
Indication: 25-49 Female Targeted	
Denominator: Age/Sex by	
Indication: 50+ Female Targeted	
Denominator: Aggregate Age/Sex	
by Indication: <15 Male Targeted	
Denominator: Aggregate Age/Sex	
by Indication: 15+ Male Targeted	
Denominator: Aggregate Age/Sex	
by Indication: <15 Female Targeted	
Denominator: Aggregate Age/Sex	
by Indication: 15+ Female Targeted	
Denominator: Aggregate Age/Sex	
by Indication: <15 Male Routine	
Denominator: Aggregate Age/Sex	
by Indication: 15+ Male Routine	
Denominator: Aggregate Age/Sex	
by Indication: <15 Female Routine	
Denominator: Aggregate Age/Sex	
by Indication: 15+ Female Routine	
Numerator Aggregated Age/Sex:	4
<15 Male	1
Numerator Aggregated Age/Sex:	
15+ Male	144
Numerator Aggregated Age/Sex:	
<15 Female	0
Numerator Aggregated Age/Sex:	400
15+ Female	123
Denominator Aggregated Age/Sex:	1



	<15 Male	
	Denominator Aggregated Age/Sex: 15+ Male	154
	Denominator Aggregated Age/Sex: <15 Female	0
	Denominator Aggregated Age/Sex: 15+ Female	132
	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	295
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	330
	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who	



are still alive and on treatment at	
12 months after initiating ART	
Age/Sed: 20-24 Male (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART	
Age/Sex: 25-49 Male (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART	
Age/Sex: 50+ Male (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART	
Age/Sex: 10-14 Female	
(Numerator: Number of adults and	
children who are still alive and on	
treatment at 12 months after	
initiating ART	
Age/Sex: 15-19 Female	
(Numerator: Number of adults and	
children who are still alive and on	
treatment at 12 months after	
initiating ART	
Age/Sex: 20-24 Female	
(Numerator: Number of adults and	
children who are still alive and on	
treatment at 12 months after	
initiating ART	
Age/Sex: 25-49 Female	
(Numerator: Number of adults and	
children who are still alive and on	
treatment at 12 months after	
initiating ART	
Age/Sex: 50+ Female (Numerator:	



Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART	
Age/Sex: >1 (Denominator: Total	
number of adults and children who	
initiated ART in the 12 months prior	
to the beginning of the reporting	
period, including those who have	
died, those who have stopped	
ART, and those lost to follow-up)	
Age/Sex: 1-9 (Denominator: Total	
number of adults and children who	
initiated ART in the 12 months prior	
to the beginning of the reporting	
period, including those who have	
died, those who have stopped	
ART, and those lost to follow-up)	
Age/Sex: 10-14 Male	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Age/Sex: 15-19 Male	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Age/Sex: 20-24 Male	
(Denominator: Total number of	
adults and children who initiated	



1
ART in the 12 months prior to the
beginning of the reporting period,
including those who have died,
those who have stopped ART, and
those lost to follow-up)
Age/Sex: 25-49 Male
(Denominator: Total number of
adults and children who initiated
ART in the 12 months prior to the
beginning of the reporting period,
including those who have died,
those who have stopped ART, and
those lost to follow-up)
Age/Sex: 50+ Male (Denominator:
Total number of adults and children
who initiated ART in the 12 months
prior to the beginning of the
reporting period, including those
who have died, those who have
stopped ART, and those lost to
follow-up)
Age/Sex: 10-14 Female
(Denominator: Total number of
adults and children who initiated
ART in the 12 months prior to the
beginning of the reporting period,
including those who have died,
those who have stopped ART, and
those lost to follow-up)
Age/Sex: 15-19 Female
(Denominator: Total number of
adults and children who initiated
ART in the 12 months prior to the
beginning of the reporting period,
including those who have died,
those who have stopped ART, and



	those lost to follow-up)
	Age/Sex: 20-24 Female
	(Denominator: Total number of
	adults and children who initiated
	ART in the 12 months prior to the
	beginning of the reporting period,
	including those who have died,
	those who have stopped ART, and
	those lost to follow-up)
	Age/Sex: 25-49 Female
	(Denominator: Total number of
	adults and children who initiated
	ART in the 12 months prior to the
	beginning of the reporting period,
	including those who have died,
	those who have stopped ART, and
	those lost to follow-up)
	Age/Sex: 50+ Female
	(Denominator: Total number of
	adults and children who initiated
	ART in the 12 months prior to the
	beginning of the reporting period,
	including those who have died,
	those who have stopped ART, and
	those lost to follow-up)
	Aggregated Age: <15 (Numerator:
	Number of adults and children who
	are still alive and on treatment at
	12 months after initiating ART)
	Aggregated Age: 15+ (Numerator:
	Number of adults and children who
	are still alive and on treatment at
	12 months after initiating ART)
	Aggregated Age: <15
	(Denominator: Total number of
	adults and children who initiated
<u> </u>	



ART in the 12 months prior to the beginning of the reporting period, including those who have stopped ART, and those lost to follow-up) Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Numerator by Status: Pregnant Numerator by Status: Breastfeeding Denominator by Status: Breastfeeding Aggregated Age/Sex: <15 Male (Numerator by Status: Breastfeeding Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
including those who have died, those who have stopped ART, and those lost to follow-up) Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Numerator by Status: Pregnant Numerator by Status: Breastfeeding Denominator by Status: Breastfeeding Denominator by Status: Breastfeeding Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	ART in the 12 months prior to the	
those who have stopped ART, and those lost to follow-up) Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Numerator by Status: Pregnant Numerator by Status: Pregnant Denominator by Status: Breastfeeding Denominator by Status: Breastfeeding Aggregated Age/Sex: <15 Male	beginning of the reporting period,	
those lost to follow-up) Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Numerator by Status: Pregnant Numerator by Status: Pregnant Denominator by Status: Pregnant Denominator by Status: Breastfeeding Denominator by Status: Breastfeeding Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	including those who have died,	
Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Numerator by Status: Pregnant Numerator by Status: Pregnant Denominator by Status: Pregnant Denominator by Status: Breastfeeding Denominator by Status: Breastfeeding Aggregated Age/Sex: <15 Male	those who have stopped ART, and	
(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Numerator by Status: Pregnant Numerator by Status: Breastfeeding Denominator by Status: Pregnant Denominator by Status: Breastfeeding Aggregated Age/Sex: <15 Male	those lost to follow-up)	
adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Numerator by Status: Pregnant Numerator by Status: Breastfeeding Denominator by Status: Breastfeeding Denominator by Status: Breastfeeding Aggregated Age/Sex: <15 Male	Aggregated Age: 15+	
ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Numerator by Status: Pregnant Numerator by Status: Pregnant Denominator by Status: Pregnant Denominator by Status: Breastfeeding Denominator by Status: Breastfeeding Aggregated Age/Sex: <15 Male	(Denominator: Total number of	
beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Numerator by Status: Pregnant Numerator by Status: Breastfeeding Denominator by Status: Breastfeeding Denominator by Status: Breastfeeding Aggregated Age/Sex: <15 Male	adults and children who initiated	
including those who have died, those who have stopped ART, and those lost to follow-up) Numerator by Status: Pregnant Numerator by Status: Breastfeeding Denominator by Status: Pregnant Denominator by Status: Breastfeeding Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on 1 treatment at 12 months after initiating ART) Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on 156 treatment at 12 months after initiating ART) Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on 156 treatment at 12 months after initiating ART) Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on 0 treatment at 12 months after initiating ART)	ART in the 12 months prior to the	
those who have stopped ART, and those lost to follow-up) Numerator by Status: Pregnant Numerator by Status: Breastfeeding Denominator by Status: Breastfeeding Aggregated Age/Sex: <15 Male	beginning of the reporting period,	
those lost to follow-up) Numerator by Status: Pregnant Numerator by Status: Breastfeeding Denominator by Status: Pregnant Denominator by Status: Pregnant Denominator by Status: Pregnant Denominator by Status: Pregnant Denominator by Status: Breastfeeding Aggregated Age/Sex: <15 Male	including those who have died,	
Numerator by Status: Pregnant Numerator by Status: Breastfeeding Denominator by Status: Pregnant Denominator by Status: Breastfeeding Aggregated Age/Sex: <15 Male	those who have stopped ART, and	
Numerator by Status: Breastfeeding Denominator by Status: Pregnant Denominator by Status: Breastfeeding Aggregated Age/Sex: <15 Male	those lost to follow-up)	
Breastfeeding Denominator by Status: Pregnant Denominator by Status: Breastfeeding Aggregated Age/Sex: <15 Male	Numerator by Status: Pregnant	
Denominator by Status: Pregnant Denominator by Status: Breastfeeding Aggregated Age/Sex: <15 Male	Numerator by Status:	
Denominator by Status: Breastfeeding Aggregated Age/Sex: <15 Male	Breastfeeding	
BreastfeedingAggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	Denominator by Status: Pregnant	
Aggregated Age/Sex: <15 Male	Denominator by Status:	
(Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)1Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)156Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)0Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)0	Breastfeeding	
children who are still alive and on treatment at 12 months after initiating ART)1Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)156Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)0Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)0	Aggregated Age/Sex: <15 Male	
treatment at 12 months after initiating ART) Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	(Numerator: Number of adults and	
initiating ART) Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on 156 treatment at 12 months after initiating ART) Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on 0 treatment at 12 months after initiating ART)	children who are still alive and on	1
Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) Aggregated Age/Sex: <15 Female	treatment at 12 months after	
(Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)156Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)0	initiating ART)	
children who are still alive and on treatment at 12 months after initiating ART) Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	Aggregated Age/Sex: 15+ Male	
treatment at 12 months after initiating ART) Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on 0 treatment at 12 months after initiating ART)	(Numerator: Number of adults and	
initiating ART) Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on 0 treatment at 12 months after initiating ART)	children who are still alive and on	156
Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on 0 treatment at 12 months after initiating ART)	treatment at 12 months after	
(Numerator: Number of adults and children who are still alive and on 0 treatment at 12 months after initiating ART)	initiating ART)	
children who are still alive and on 0 treatment at 12 months after initiating ART)	Aggregated Age/Sex: <15 Female	
treatment at 12 months after initiating ART)	(Numerator: Number of adults and	
initiating ART)	children who are still alive and on	0
	treatment at 12 months after	
Aggregated Age/Sex: 15+ Female 138	initiating ART)	
	Aggregated Age/Sex: 15+ Female	138



	(Numerator: Number of adults and children who are still alive and on treatment at 12 months after	
	initiating ART)	
	Aggregated Age/Sex: <15 Male	
	(Denominator: Total number of	
	adults and children who initiated	
	ART in the 12 months prior to the	1
	beginning of the reporting period,	
	including those who have died,	
	those who have stopped ART, and	
	those lost to follow-up)	
	Aggregated Age/Sex: 15+ Male	
	(Denominator: Total number of	
	adults and children who initiated	
	ART in the 12 months prior to the	
	beginning of the reporting period,	177
	including those who have died,	
	those who have stopped ART, and	
	those lost to follow-up)	
	Aggregated Age/Sex: <15 Female	
	(Denominator: Total number of	
	adults and children who initiated	
	ART in the 12 months prior to the	
	beginning of the reporting period,	0
	including those who have died,	
	those who have stopped ART, and	
	those lost to follow-up)	
	Aggregated Age/Sex: 15+ Female	
	(Denominator: Total number of	
	,	
	adults and children who initiated	
	ART in the 12 months prior to the	152
	beginning of the reporting period,	
	including those who have died,	
	those who have stopped ART, and	
	those lost to follow-up)	





Technical Area Summary Indicators and Targets

Laos

Indicator Number	Label	2017
	KP_PREV_DSD Percentage of key	
	populations reached with individual	
	and/or small group level HIV	
	preventive interventions that are	n/a
	based on evidence and/or meet the	
	minimum standards required (DSD)	
	Number of key populations reached	
	with individual and/or small group	
	level HIV preventive interventions	4,020
	that are based on evidence and/or	4,020
	meet the minimum standards	
	required	
	Total estimated number of key	
	population in the catchment area	
KP_PREV_DSD	By key population type: Men who	
	have sex with men who are sex	
	workers (Numerator: Number of	
	key populations reached with	
	individual and/or small group level	
	HIV preventive interventions that	
	are based on evidence and/or meet	
	the minimum standards required)	
	By key population type: Men who	
	have sex with men who are NOT	
	sex workers (Numerator: Number	
	of key populations reached with	
	individual and/or small group level	
	HIV preventive interventions that	
	are based on evidence and/or meet	



	the minimum standards required)
	By key population type:
	Transgender who are sex workers
	(Numerator: Number of key
	populations reached with individual
	and/or small group level HIV
	preventive interventions that are
	based on evidence and/or meet the
	minimum standards required)
	By key population type:
	Transgender who are NOT sex
	workers (Numerator: Number of
	key populations reached with
	individual and/or small group level
	HIV preventive interventions that
	are based on evidence and/or meet
	the minimum standards required)
	By key population type: Female
	sex workers (FSW) (Numerator:
	Number of key populations reached
	with individual and/or small group
	level HIV preventive interventions
	that are based on evidence and/or
	meet the minimum standards
	required)
	By key population type: Males who
	inject drugs (Male PWID)
	(Numerator: Number of key
	populations reached with individual
	and/or small group level HIV
	preventive interventions that are
	based on evidence and/or meet the
	minimum standards required)
	By key population type: Females
	who inject drugs (Female PWID)
	(Numerator: Number of key
L	



· · · · · · · · · · · · · · · · · · ·
populations reached with individual
and/or small group level HIV
preventive interventions that are
based on evidence and/or meet the
minimum standards required)
By key population type: People in
prisons and enclosed settings
(Numerator: Number of key
populations reached with individual
and/or small group level HIV
preventive interventions that are
based on evidence and/or meet the
minimum standards required)
By key population type: Men who
have sex with men who are sex
workers (Denominator: Total
estimated number of key
population in the catchment area
By key population type: Men who
have sex with men who are NOT
sex workers (Denominator: Total
estimated number of key
population in the catchment area)
By key population type:
Transgender who are sex workers
(Denominator: Total estimated
number of key population in the
catchment area)
By key population type:
Transgender who are NOT sex
workers (Denominator: Total
estimated number of key
population in the catchment area)
By key population type: Female
sex workers (FSW) (Denominator:
Total estimated number of key



	population in the catchment area)	
	By key population type: Males who	
	inject drugs (Male PWID)	
	(Denominator: Total estimated	
	` number of key population in the	
	catchment area)	
	By key population type: Females	
	who inject drugs (Female PWID)	
	(Denominator: Total estimated	
	number of key population in the	
	catchment area)	
	By key population type: People in	
	prisons and enclosed settings	
	(Denominator: Total estimated	
	number of key population in the	
	catchment area)	
	By Service: KP known status	
	By Service: KP was tested as part	
	of the program and/or KP was	
	referred for testing as part of the	
	program	
	By New Client Status: New	
	beneficiary	
	By New Client Status: REturniong	
	beneficiary within the current report	
	period	
	Number of individuals who received	
	T&C services for HIV and received	1,024
HTC_TST_DSD	their test results during the past 12 months	
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	



Age/sex: 50+ Male
Age/sex: 5-9 Female
Age/sex: 10-14 Female
Age/sex: 15-19 Female
Age/sex: 20-24 Female
Age/sex: 25-49 Female
Age/sex: 50+ Female
Test Result by Age and Sex:
Positive: 10-14 Male
Test Result by Age and Sex:
Positive: 15-19 Male
Test Result by Age and Sex:
Positive: 20-24 Male
Test Result by Age and Sex:
Positive: 25-49 Male
Test Result by Age and Sex:
Positive: 50+ Male
Test Result by Age and Sex:
Positive: 10-14 Female
Test Result by Age and Sex: Positive: 15-19 Female
Test Result by Age and Sex: Positive: 20-24 Female
Test Result by Age and Sex:
Positive: 25-49 Female
Test Result by Age and Sex:
Positive: 50+ Female
Test Result by Age and Sex:
Negative: 10-14 Male
Test Result by Age and Sex:
Negative: 15-19 Male
Test Result by Age and Sex:
Negative: 20-24 Male
Test Result by Age and Sex:



Negative: 25-49 Male	
Test Result by Age and Sex:	
Negative: 50+ Male	
Test Result by Age and Sex:	
Negative: 10-14 Female	
Test Result by Age and Sex:	
Negative: 15-19 Female	
Test Result by Age and Sex:	
Negative: 20-24 Female	
Test Result by Age and Sex:	
Negative: 25-49 Female	
Test Result by Age and Sex:	
Negative: 50+ Female	
Aggregated Age/sex - USE WITH	
HQ PERMISSION ONLY: <15 Male	
Aggregated Age/sex - USE WITH	1,024
HQ PERMISSION ONLY: 15+ Male	1,021
Aggregated Age/sex - USE WITH	
HQ PERMISSION ONLY: <15	
Female	
Aggregated Age/sex - USE WITH	
HQ PERMISSION ONLY: 15+	
Test Result by Aggregated Age and Sex: Negative <15 Male	
Test Result by Aggregated Age and Sex: Negative 15+ Male	
Test Result by Aggregated Age	
and Sex: Negative <15 Female	
Test Result by Aggregated Age	
and Sex: Negative 15+ Female	
Test Result by Aggregated Age	
and Sex: Positive <15 Male	
Test Result by Aggregated Age	72



and Sex: Positive 15+ Male
Test Result by Aggregated Age
and Sex: Positive <15 Female
Test Result by Aggregated Age
and Sex: Positive 15+ Female
Test Result by Age: Positive: <1
Test Result by Age: Positive: 1-9
Age/sex: <1
Age/sex: 1-9
Service Delivery Point
(Community): Index testing
Service Delivery Point
(Community): Homebased testing
Service Delivery Point
(Community): Mobile testing
Service Delivery Point
(Community): Other
Service Delivery Point (Community)
by Age: <15 index testing
Service Delivery Point (Community)
by Age: 15+ index testing
Service Delivery Point (Community)
by Age: <15 homebased testing
Service Delivery Point (Community)
by Age: 15+ homebased testing
Service Delivery Point (Community)
by Age: <15 mobile testing
Service Delivery Point (Community)
by Age: 15+ mobile testing
Service Delivery Point (Community)
by Age: <15 other
Service Delivery Point (Community)
by Age: <15 other
Service Delivery Point (Facility):



Inpatient
Service Delivery Point (Facility):
Outpatient
Service Delivery Point (Facility):
Pediatric
Service Delivery Point (Facility):
Malnutrition facilities
Service Delivery Point (Facility):
Other PITC
Service Delivery Point (Facility):
VCT
Service Delivery Point (Facility):
VMMC
Service Delivery Point (Facility):
Service Delivery Point (Facility): TB
Service Delivery Point (Facility): Index testing
Service Delivery Point (Facility) by Age: <15 Inpatient
Service Delivery Point (Facility) by
Age: >15 Inpatient
Service Delivery Point (Facility) by
Age: <15 Outpatient
Service Delivery Point (Facility) by
Age: >15 Outpatient
Service Delivery Point (Facility) by
Age: <15 Pediatroc
Service Delivery Point (Facility) by
Age: >15 Pediatroc
Service Delivery Point (Facility) by
Age: <15 Malnutrition facilities
Service Delivery Point (Facility) by



	Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by	
	Age: <15 Other PITC	
	Service Delivery Point (Facility) by	
	Age: >15 Other PITC	
	Service Delivery Point (Facility) by	
	Age: <15 VCT	
	Service Delivery Point (Facility) by	
	Age: >15 VCT	
	Service Delivery Point (Facility) by	
	Age: <15 VMMC	
	Service Delivery Point (Facility) by	
	Age: >15 VMMC	
	Service Delivery Point (Facility) by	
	Age: <15 PMTCT	
	Service Delivery Point (Facility) by	
	Age: >15 PMTCT	
	Service Delivery Point (Facility) by	
	Age: <15 TB Clinics	
	Service Delivery Point (Facility) by	
	Age: >15 TB Clinics	
	Service Delivery Point (Facility) by	
	Age: <15 Index testing	
	Service Delivery Point (Facility) by	
	Age: >15 Index testing	
	Number of individuals who received	
	T&C services for HIV and received	3,038
HTC_TST_TA	their test results during the past 12	
	months	
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	



Age/sex: 50+ Male
Age/sex: 5-9 Female
Age/sex: 10-14 Female
Age/sex: 15-19 Female
Age/sex: 20-24 Female
Age/sex: 25-49 Female
Age/sex: 50+ Female
Test Result by Age and Sex:
Positive: 10-14 Male
Test Result by Age and Sex:
Positive: 15-19 Male
Test Result by Age and Sex:
Positive: 20-24 Male
Test Result by Age and Sex:
Positive: 25-49 Male
Test Result by Age and Sex:
Positive: 50+ Male
Test Result by Age and Sex:
Positive: 10-14 Female
Test Result by Age and Sex:
Positive: 15-19 Female
Test Result by Age and Sex:
Positive: 20-24 Female
Test Result by Age and Sex:
Positive: 25-49 Female
Test Result by Age and Sex:
Positive: 50+ Female
Test Result by Age and Sex:
Negative: 10-14 Male
Test Result by Age and Sex:
Negative: 15-19 Male
Test Result by Age and Sex:
Negative: 20-24 Male
Test Result by Age and Sex:



Negative: 25-49 Male	
Test Result by Age and Sex:	
Negative: 50+ Male	
Test Result by Age and Sex:	
Negative: <1 Female	
Test Result by Age and Sex:	
Negative: 10-14 Female	
Test Result by Age and Sex:	
Negative: 15-19 Female	
Test Result by Age and Sex:	
Negative: 20-24 Female	
Test Result by Age and Sex:	
Negative: 25-49 Female	
Test Result by Age and Sex:	
Negative: 50+ Female	
Aggregated Age/sex - USE WITH	
HQ PERMISSION ONLY: <15 Male	
Aggregated Age/sex - USE WITH	3,038
HQ PERMISSION ONLY: 15+ Male	- ,
Aggregated Age/sex - USE WITH	
HQ PERMISSION ONLY: <15	
Female	
Aggregated Age/sex - USE WITH	
HQ PERMISSION ONLY: 15+ Female	
Test Result by Aggregated Age	
and Sex: Negative <15 Male	
Test Result by Aggregated Age	
and Sex: Negative 15+ Male	
Test Result by Aggregated Age	
and Sex: Negative <15 Female	
Test Result by Aggregated Age	
and Sex: Negative 15+ Female	
Test Result by Aggregated Age	



1	
and Sex: Positive <15 Male	
Test Result by Aggregated Age	32
and Sex: Positive 15+ Male	32
Test Result by Aggregated Age	
and Sex: Positive <15 Female	
Test Result by Aggregated Age	
and Sex: Positive 15+ Female	
Test Result by Age: Positive: <1	
Test Result by Age: Positive: 1-9	
Age/sex: <1	
Age/sex: 1-9	
Service Delivery Point	
(Community): Index testing	
Service Delivery Point	
(Community): Homebased testing	
Service Delivery Point	
(Community): Mobile testing	
Service Delivery Point	
(Community): Other	
Service Delivery Point (Community)	
by Age: <15 index testing	
Service Delivery Point (Community)	
by Age: 15+ index testing	
Service Delivery Point (Community)	
by Age: <15 homebased testing	
Service Delivery Point (Community)	
by Age: 15+ homebased testing	
Service Delivery Point (Community)	
by Age: <15 mobile testing	
Service Delivery Point (Community)	
by Age: 15+ mobile testing	
Service Delivery Point (Community)	
by Age: <15 other	
Service Delivery Point (Community)	



by Age: <15 other	
Service Delivery Point (Facility):	
Inpatient	
Service Delivery Point (Facility):	
Outpatient	
Service Delivery Point (Facility):	
Pediatric	
Service Delivery Point (Facility):	
Malnutrition facilities	
Service Delivery Point (Facility):	
Other PITC	
Service Delivery Point (Facility):	050
VCT	650
Service Delivery Point (Facility):	
VMMC	
Service Delivery Point (Facility):	
РМТСТ	
Service Delivery Point (Facility): TB	
Clinics	
Service Delivery Point (Facility):	
Index testing	
Index testing Service Delivery Point (Facility) by	
Service Delivery Point (Facility) by	
Service Delivery Point (Facility) by Age: <15 Inpatient	
Service Delivery Point (Facility) by Age: <15 Inpatient Service Delivery Point (Facility) by	
Service Delivery Point (Facility) by Age: <15 Inpatient Service Delivery Point (Facility) by Age: >15 Inpatient	
Service Delivery Point (Facility) by Age: <15 Inpatient Service Delivery Point (Facility) by Age: >15 Inpatient Service Delivery Point (Facility) by	
Service Delivery Point (Facility) by Age: <15 Inpatient Service Delivery Point (Facility) by Age: >15 Inpatient Service Delivery Point (Facility) by Age: <15 Outpatient	
Service Delivery Point (Facility) by Age: <15 Inpatient Service Delivery Point (Facility) by Age: >15 Inpatient Service Delivery Point (Facility) by Age: <15 Outpatient Service Delivery Point (Facility) by	
Service Delivery Point (Facility) by Age: <15 Inpatient Service Delivery Point (Facility) by Age: >15 Inpatient Service Delivery Point (Facility) by Age: <15 Outpatient Service Delivery Point (Facility) by Age: >15 Outpatient	
Service Delivery Point (Facility) by Age: <15 Inpatient Service Delivery Point (Facility) by Age: >15 Inpatient Service Delivery Point (Facility) by Age: <15 Outpatient Service Delivery Point (Facility) by Age: >15 Outpatient Service Delivery Point (Facility) by	
Service Delivery Point (Facility) by Age: <15 Inpatient Service Delivery Point (Facility) by Age: >15 Inpatient Service Delivery Point (Facility) by Age: <15 Outpatient Service Delivery Point (Facility) by Age: >15 Outpatient Service Delivery Point (Facility) by Age: <15 Outpatient	



	Age: <15 Malnutrition facilities	
	Service Delivery Point (Facility) by	
	Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by	
	Age: <15 Other PITC	
	Service Delivery Point (Facility) by	
	Age: >15 Other PITC	
	Service Delivery Point (Facility) by	
	Age: <15 VCT	
	Service Delivery Point (Facility) by	
	Age: >15 VCT	
	Service Delivery Point (Facility) by	
	Age: <15 VMMC	
	Service Delivery Point (Facility) by	
	Age: >15 VMMC	
	Service Delivery Point (Facility) by	
	Age: <15 PMTCT	
	Service Delivery Point (Facility) by	
	Age: >15 PMTCT	
	Service Delivery Point (Facility) by	
	Age: <15 TB Clinics	
	Service Delivery Point (Facility) by	
	Age: >15 TB Clinics	
	Service Delivery Point (Facility) by	
	Age: <15 Index testing	
	Service Delivery Point (Facility) by	
	Age: >15 Index testing	
	Number of adults and children	
	receiving antiretroviral therapy	2,395
	(ART)	
TX_CURR_TA	Age/Sex: <1 Male	
	Age/Sex: 1-4 Male	
	Age/Sex: 5-14 Male	
	Age/Sex: 15-19 Male	



Age/Sex: 20+ Male	
Age/Sex: <1 Female	
Age/Sex: 1-4 Female	
Age/Sex: 5-14 Female	
Age/Sex: 15-19 Female	
Age/Sex: 20+ Female	
Sum of Age/Sex disaggregations	
Aggregated Age/Sex: <1 Male	
Aggregated Age/Sex: <1 Female	
Aggregated Age/Sex: <15 Male	68
Aggregated Age/Sex: 1-14 Male	
Aggregated Age/Sex: 15+ Male	1,109
Aggregated Age/Sex: <15 Female	74
Aggregated Age/Sex: 1-14 Female	
Aggregated Age/Sex: 15+ Female	1,042
Sum of Aggregated Age/Sex <15	142
Sum of Aggregated Age/Sex 15+	2,151
Sum of Aggregated Age/Sex	2 202
disaggregates	2,293
Age/Sex: <1	
Age/Sex: 1-9	
Age/Sex: 10-14 Male	
Age/Sex: 10-14 Female	
Sum of Aggregated Age/Sex (<1	
and 1-14) <15	
Age/Sex: 20-24 Male	
Age/Sex: 25-49 Male	
Age/Sex: 50+ Male	
Age/Sex: 20-24 Female	
Age/Sex: 25-49 Female	
Age/Sex: 50+ Female	
Number of adults and children	617
	Age/Sex: <1 FemaleAge/Sex: 1-4 FemaleAge/Sex: 5-14 FemaleAge/Sex: 15-19 FemaleAge/Sex: 20+ FemaleSum of Age/Sex disaggregationsAggregated Age/Sex: <1 Male



newly enrolled on antiretroviral	
therapy (ART)	
By Age/Sex: <1	
By Age/Sex: 1-9	
By Age/Sex: <1 Male	
By Age/Sex: 1-4 Male	
By Age/Sex: 5-9 Male	
By Age/Sex: 10-14 Male	
By Age/Sex: 15-19 Male	
By Age/Sex: 20-24 Male	
By Age/Sex: 25-49 Male	
By Age/Sex: 50+ Male	
By Age/Sex: <1 Female	
By Age/Sex: 1-4 Female	
By Age/Sex: 5-9 Female	
By Age/Sex: 10-14 Female	
By Age/Sex: 15-19 Female	
By Age/Sex: 20-24 Female	
By Age/Sex: 25-49 Female	
By Age/Sex: 50+ Female	
Sum of Age/Sex disaggregates	
Aggregated Grouping by Age: <1	
Aggregated Grouping by Age: <1 Male	
Aggregated Grouping by Age/Sex: <15 Male	17
Aggregated Grouping by Age/Sex: 1-14 Male	
Aggregated Grouping by Age/Sex: 15+ Male	222
Aggregated Grouping by Age: <1 Female	
 Aggregated Grouping by Age/Sex:	19



	<15 Female	
	Aggregated Grouping by Age/Sex: 1-14 Female	
	Aggregated Grouping by Age/Sex: 15+ Female	290
	Sum of Aggregated Age/Sex disaggregates	548
	Pregnancy status	
	Breastfeeding status	
	TX_PVLS_TA Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	n/a
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	977
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	1,026
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 1-9 Targeted	



Numerator: Age/Sex by Indication: 10-14 Female Routine
Numerator: Age/Sex by Indication: 10-14 Female Targeted
Numerator: Age/Sex by Indication: 10-14 Male Routine
Numerator: Age/Sex by Indication: 10-14 Male Targeted
Numerator: Age/Sex by Indication: 15-19 Female Routine
Numerator: Age/Sex by Indication: 15-19 Female Targeted
Numerator: Age/Sex by Indication: 15-19 Male Routine
Numerator: Age/Sex by Indication: 15-19 Male Targeted
Numerator: Age/Sex by Indication: 20-24 Female Routine
Numerator: Age/Sex by Indication: 20-24 Female Targeted
Numerator: Age/Sex by Indication: 20-24 Male Routine
Numerator: Age/Sex by Indication: 20-24 Male Targeted
Numerator: Age/Sex by Indication: 25-49 Female Routine
Numerator: Age/Sex by Indication: 25-49 Female Targeted
Numerator: Age/Sex by Indication: 25-49 Male Routine
Numerator: Age/Sex by Indication: 25-49 Male Targeted
Numerator: Age/Sex by Indication: 50+ Female Routine



۱	
Numerator: Age/Sex by Indication: 50+ Female Targeted	
Numerator: Age/Sex by Indication: 50+ Male Routine	
Numerator: Age/Sex by Indication: 50+ Male Targeted	
Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	
Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	
Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	
Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	
Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	
Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	
Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
Numerator: Indication: Routine Numerator: Indication: Targeted	977
Numerator: Preg/BF by Indication: Breastfeeding Routine	
Numerator: Preg/BF by Indication: Breastfeeding Targeted	
Numerator: Preg/BF by Indication: Pregnant Routine	
Numerator: Preg/BF by Indication: Pregnant Targeted	
Denominator: Indication: Routine	1,025
 Denominator: Indication: Targeted	



<u> </u>
Denominator: Age/Sex by
Indication: <1 Routine
Denominator: Age/Sex by
Indication: <1 Targeted
Denominator: Age/Sex by
Indication: 1-9 Routine
Denominator: Age/Sex by
Indication: 1-9 Targeted
Denominator: Age/Sex by
Indication: 10-14 Female Routine
Denominator: Age/Sex by
Indication: 10-14 Female Targeted
Denominator: Age/Sex by
Indication: 10-14 Male Routine
Denominator: Age/Sex by
Indication: 10-14 Male Targeted
Denominator: Age/Sex by
Indication: 15-19 Female Routine
Denominator: Age/Sex by
Indication: 15-19 Female Targeted
Denominator: Age/Sex by
Indication: 15-19 Male Routine
Denominator: Age/Sex by
Indication: 15-19 Male Targeted
Denominator: Age/Sex by
Indication: 20-24 Female Routine
Denominator: Age/Sex by
Indication: 20-24 Female Targeted
Denominator: Age/Sex by
Indication: 20-24 Male Routine
Denominator: Age/Sex by
Indication: 20-24 Male Targeted
Denominator: Age/Sex by
Indication: 25-49 Female Routine
· · · · · · · · · · · · · · · · · · ·



Denominator: Age/Sex by Indication: 25-49 Female Targeted
Indication: 25-49 Female Targeted
Denominator: Age/Sex by
Indication: 25-49 Male Routine
Denominator: Age/Sex by
Indication: 25-49 Male Targeted
Denominator: Age/Sex by
Indication: 50+ Female Routine
Denominator: Age/Sex by
Indication: 50+ Female Targeted
Denominator: Age/Sex by
Indication: 50+ Male Routine
Denominator: Age/Sex by
Indication: 50+ Male Targeted
Denominator: Aggregate Age/Sex
by Indication: <15 Female Routine
Denominator: Aggregate Age/Sex
by Indication: <15 Female Targeted
Denominator: Aggregate Age/Sex
by Indication: <15 Male Routine
Denominator: Aggregate Age/Sex
by Indication: <15 Male Targeted
Denominator: Aggregate Age/Sex
by Indication: 15+ Female Routine
Denominator: Aggregate Age/Sex
by Indication: 15+ Female Targeted
Denominator: Aggregate Age/Sex
by Indication: 15+ Male Routine
Denominator: Aggregate Age/Sex
by Indication: 15+ Male Targeted
Denominator: Preg/BF by
Indication: Breastfeeding Routine
Denominator: Preg/BF by
Indication: Breastfeeding Targeted



	Depeminetor: Breg/RE by	
	Denominator: Preg/BF by	
	Indication: Pregnant Routine	
	Denominator: Preg/BF by	
	Indication: Pregnant Targeted	
	Numerator Aggregated Age/Sex: <15 Male	25
	Numerator Aggregated Age/Sex: 15+ Male	472
	Numerator Aggregated Age/Sex: <15 Female	24
	Numerator Aggregated Age/Sex: 15+ Female	456
	Denominator Aggregated Age/Sex: <15 Male	26
	Denominator Aggregated Age/Sex: 15+ Male	495
	Denominator Aggregated Age/Sex: <15 Female	25
	Denominator Aggregated Age/Sex: 15+ Female	480
	TX_RET_TA Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	493
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	548
	Age/Sex: <1 (Numerator: Number	



ł	1
of adults and children who are still	
alive and on treatment at 12	
months after initiating ART)	
Age/Sex: 1-9 (Numerator: Number	
of adults and children who are still	
alive and on treatment at 12	
months after initiating ART)	
Age/Sex: 10-14 Male (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART)	
Age/Sex: 15-19 Male (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART)	
Age/Sex: 20-24 Male (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART)	
Age/Sex: 25-49 Male (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART)	
Age/Sex: 50+ Male (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART)	
Age/Sex: 10-14 Female	
(Numerator: Number of adults and	
children who are still alive and on	
treatment at 12 months after	
initiating ART)	
Age/Sex: 15-19 Female	
(Numerator: Number of adults and	
children who are still alive and on	



treatment at 12 months after	
initiating ART)	
Age/Sex: 20-24 Female	
(Numerator: Number of adults and	
children who are still alive and on	
treatment at 12 months after	
initiating ART)	
Age/Sex: 25-49 Female	
(Numerator: Number of adults and	
children who are still alive and on	
treatment at 12 months after	
initiating ART)	
Age/Sex: 50+ Female (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART)	
Age/Sex: <1 (Denominator: Total	
number of adults and children who	
initiated ART in the 12 months prior	
to the beginning of the reporting	
period, including those who have	
died, those who have stopped	
ART, and those lost to follow-up)	
Age/Sex: 1-9 (Denominator: Total	
number of adults and children who	
initiated ART in the 12 months prior	
to the beginning of the reporting	
period, including those who have	
died, those who have stopped	
ART, and those lost to follow-up)	
Age/Sex: 10-14 Male	_
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	



those who have stopped ART, and
those lost to follow-up)
Age/Sex: 15-19 Male
(Denominator: Total number of
adults and children who initiated
ART in the 12 months prior to the
beginning of the reporting period,
including those who have died,
those who have stopped ART, and
those lost to follow-up)
Age/Sex: 20-24 Male
(Denominator: Total number of
adults and children who initiated
ART in the 12 months prior to the
beginning of the reporting period,
including those who have died,
those who have stopped ART, and
those lost to follow-up)
Age/Sex: 25-49 Male
Age/Sex: 25-49 Male (Denominator: Total number of
(Denominator: Total number of
(Denominator: Total number of adults and children who initiated
(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the
(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,
(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died,
(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)
(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and
(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 50+ Male (Denominator:
(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 50+ Male (Denominator: Total number of adults and children
(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months
(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the
(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those
(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have
(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)
(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to



adults and children who initiated
ART in the 12 months prior to the
beginning of the reporting period,
including those who have died,
those who have stopped ART, and
those lost to follow-up)
Age/Sex: 15-19 Female
(Denominator: Total number of
adults and children who initiated
ART in the 12 months prior to the
beginning of the reporting period,
including those who have died,
those who have stopped ART, and
those lost to follow-up)
Age/Sex: 20-24 Female
(Denominator: Total number of
adults and children who initiated
ART in the 12 months prior to the
beginning of the reporting period,
including those who have died,
those who have stopped ART, and
those lost to follow-up)
Age/Sex: 25-49 Female
(Denominator: Total number of
adults and children who initiated
ART in the 12 months prior to the
beginning of the reporting period,
including those who have died,
those who have stopped ART, and
those lost to follow-up)
Age/Sex: 50+ Female
(Denominator: Total number of
adults and children who initiated
ART in the 12 months prior to the
beginning of the reporting period,
including those who have died,



	those who have stopped ART, and	
	those lost to follow-up)	
	Aggregated Age: <15 (Numerator:	
	Number of adults and children who	
	are still alive and on treatment at	
	12 months after initiating ART)	
	Aggregated Age: 15+ (Numerator:	
	Number of adults and children who	
	are still alive and on treatment at	
	12 months after initiating ART)	
	Aggregated Age: <15	
	(Denominator: Total number of	
	adults and children who initiated	
	ART in the 12 months prior to the	
	beginning of the reporting period,	
	including those who have died,	
	those who have stopped ART, and	
	those lost to follow-up)	
	Aggregated Age: 15+	
	(Denominator: Total number of	
	adults and children who initiated	
	ART in the 12 months prior to the	
	beginning of the reporting period,	
	including those who have died,	
	those who have stopped ART, and	
	those lost to follow-up)	
	Numerator by Status: Pregnant	
	Numerator by Status:	
	Breastfeeding	
	Denominator by Status: Pregnant	
	Denominator by Status:	
	Breastfeeding	
	Aggregated Age/Sex: <15 Male	
	(Numerator: Number of adults and	15
	children who are still alive and on	
L		



treatment at 12 months after initiating ART)	
Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	200
Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	17
Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	261
Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	17
Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	222
Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated	19



	ART in the 12 months prior to the	
	beginning of the reporting period,	
	including those who have died,	
	those who have stopped ART, and	
	those lost to follow-up)	
	Aggregated Age/Sex: 15+ Female	
	(Denominator: Total number of	
	adults and children who initiated	
	ART in the 12 months prior to the	000
	beginning of the reporting period,	290
	including those who have died,	
	those who have stopped ART, and	
	those lost to follow-up)	
	Percentage of laboratories and	
	POC testing sites that perform HIV	
	diagnostic testing that participate	
	and successfully pass in an	
	analyte-specific proficiency testing	
	(PT) program	
	CD4: Number of laboratories that	
	achieve acceptable successful	3
	passing criteria in this PT program	
	CD4: Number of laboratories that	_
	participate in this PT program	4
LAB_PT_TA	CD4: Number of laboratories that	
	perform this testing	
	Early infant diagnostics: Number of	
	laboratories that achieve	
	acceptable successful passing	
	criteria in this PT program	
	Early infant diagnostics: Number of	
	laboratories that participate in this	
	PT program	
	Early infant diagnostics: Number of	
	laboratories that perform this	



testing	
HIV serologic/diagnostic testing:	
Number of laboratories that	
achieve acceptable successful	53
passing criteria in this PT program	
HIV serologic/diagnostic testing: Number of laboratories that	70
	70
participate in this PT program	
HIV serologic/diagnostic testing:	
Number of laboratories that	
perform this testing	
HIV viral load: Number of	
laboratories that achieve	
acceptable successful passing	
criteria in this PT program	
HIV viral load: Number of	
laboratories that participate in this	
PT program	
HIV viral load: Number of	
laboratories that perform this	
testing	
TB diagnostics (AFB microscopy):	
Number of laboratories that	
achieve acceptable successful	
passing criteria in this PT program	
TB diagnostics (AFB microscopy):	
Number of laboratories that	
participate in this PT program	
TB diagnostics (AFB microscopy):	
Number of laboratories that	
perform this testing	
TB diagnostics (Xpert MTB/RIF):	
Number of laboratories that	
achieve acceptable successful	
passing criteria in this PT program	



	TB diagnostics (Xpert MTB/RIF):	
	Number of laboratories that	
	participate in this PT program	
	TB diagnostics (Xpert MTB/RIF):	
	Number of laboratories that	
	perform this testing	
	TB diagnostics (Culture/DST):	
	Number of laboratories that	
	achieve acceptable successful	
	passing criteria in this PT program	
	TB diagnostics (Culture/DST):	
	Number of laboratories that	
	participate in this PT program	
	TB diagnostics (Culture/DST):	
	Number of laboratories that	
	perform this testing	
	Number of new HCW who	
	graduated from a pre-service	
	training institution or program as a	185
	result of PEPFAR-supported	105
	strengthening efforts, within the	
	reporting period, by select cadre	
	By Graduates: Doctors	
HRH_PRE	By Graduates: Nurses	
	By Graduates: Midwives	
	By Graduates: Social service	
	workers	
	By Graduates: Laboratory	
	professionals	
	By Graduates: Other	
	Sum of Graduates disaggreagtes	
	Sum of Graduales disaygreagles	



Technical Area Summary Indicators and Targets

Thailand

Indicator Number	Label	2017
KP_MAT_TA	KP_MAT_TA Percentage of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	n/a
	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	6,976
	Sex: Female	698
	Sex: Male	6,278
	Sum of Sex Disaggregates	6,976
	PrEP_NEW_DSD Number of individuals who have received antiretroviral pre-exposure prophylaxis (PrEP) to prevent HIV infection in the reporting period.	n/a
	Number of individuals who have received antiretroviral preexposure	750
	Male 10-14	
PrEP_NEW_DSD	Male 15-19	
	Male 20-24	
	Male 25-49	
	Male 50+	
	Female 10-14	
	Female 15-19	
	Female 20-24	
	Female 25-49	
	Female 50+	



	PrEP_NEW_TA Number of adult	
	women and adolecent girls newly	n/a
	enrolled on oral or topical PrEP	
	Number of adult women and	
	adolecent girls newly enrolled on	621
	oral or topical PrEP	
	Male 10-14	
	Male 15-19	
PrEP_NEW_TA	Male 20-24	580
	Male 25-49	
	Male 50+	
	Female 10-14	
	Female 15-19	
	Female 20-24	41
	Female 25-49	
	Female 50+	
	KP_PREV_DSD Percentage of key	
	populations reached with individual	
	and/or small group level HIV	
	preventive interventions that are	n/a
	based on evidence and/or meet the	
	minimum standards required (DSD)	
	Number of key populations reached	
	with individual and/or small group	
	level HIV preventive interventions	00.000
KP_PREV_DSD	that are based on evidence and/or	82,983
	meet the minimum standards	
	required	
	Total estimated number of key	
	population in the catchment area	
	By key population type: Men who	
	have sex with men who are sex	
	workers (Numerator: Number of	
	key populations reached with	



individual and/or small group level	
HIV preventive interventions that	
are based on evidence and/or meet	
the minimum standards required)	
By key population type: Men who	
have sex with men who are NOT	
sex workers (Numerator: Number	
of key populations reached with	
individual and/or small group level	
HIV preventive interventions that	
are based on evidence and/or meet	
the minimum standards required)	
By key population type:	
Transgender who are sex workers	
(Numerator: Number of key	
populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type:	
Transgender who are NOT sex	
workers (Numerator: Number of	
key populations reached with	
individual and/or small group level	
HIV preventive interventions that	
are based on evidence and/or meet	
the minimum standards required)	
By key population type: Female	
sex workers (FSW) (Numerator:	
Number of key populations reached	
with individual and/or small group	
level HIV preventive interventions	
that are based on evidence and/or	
meet the minimum standards	
required)	
·	



By key population type: Males who
inject drugs (Male PWID)
(Numerator: Number of key
populations reached with individual
and/or small group level HIV
preventive interventions that are
based on evidence and/or meet the
minimum standards required)
By key population type: Females
who inject drugs (Female PWID)
(Numerator: Number of key
populations reached with individual
and/or small group level HIV
preventive interventions that are
based on evidence and/or meet the
minimum standards required)
By key population type: People in
prisons and enclosed settings
(Numerator: Number of key
populations reached with individual
and/or small group level HIV
preventive interventions that are
based on evidence and/or meet the
minimum standards required)
By key population type: Men who
have sex with men who are sex
workers (Denominator: Total
estimated number of key
population in the catchment area
By key population type: Men who
have sex with men who are NOT
sex workers (Denominator: Total
estimated number of key
population in the catchment area)
By key population type:
Transgender who are sex workers
TRUSYCHUCK WITH ALE SEA WULKETS



(Denominator: Total estimated	
number of key population in the	
catchment area)	
By key population type:	
Transgender who are NOT sex	
workers (Denominator: Total	
estimated number of key	
population in the catchment area)	
By key population type: Female	
sex workers (FSW) (Denominator:	
Total estimated number of key	
population in the catchment area)	
By key population type: Males who	
inject drugs (Male PWID)	
(Denominator: Total estimated	
number of key population in the	
catchment area)	
By key population type: Females	
who inject drugs (Female PWID)	
(Denominator: Total estimated	
number of key population in the	
catchment area)	
By key population type: People in	
prisons and enclosed settings	
Denominator: Total estimated	
number of key population in the	
catchment area)	
By Service: KP known status	
By Service: KP was tested as part	
of the program and/or KP was	
referred for testing as part of the	
program	
By New Client Status: New	
beneficiary	
By New Client Status: REturniong	



	beneficiary within the current report	
	period	
	KP_PREV_TA Percentage of key	
	populations reached with individual	
	and/or small group level HIV	
	preventive interventions that are	n/a
	based on evidence and/or meet the	
	minimum standards required	
	(TA-only)	
	Number of key populations reached	
	with individual and/or small group	
	level HIV preventive interventions	2,500
	that are based on evidence and/or	2,500
	meet the minimum standards	
	required	
	Total estimated number of key	
	population in the catchment area	
	By key population type: Female	
KP_PREV_TA	sex workers (FSW) (Numerator:	
	Number of key populations reached	
	with individual and/or small group	
	level HIV preventive interventions	
	that are based on evidence and/or	
	meet the minimum standards	
	required)	
	By key population type: Males who	
	inject drugs (Male PWID)	
	(Numerator: Number of key	
	populations reached with individual	
	and/or small group level HIV	
	preventive interventions that are	
	based on evidence and/or meet the	
	minimum standards required)	
	By key population type: Females	
	who inject drugs (Female PWID)	
	(Numerator: Number of key	



populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type: Female	
sex workers (FSW) (Denominator:	
Total estimated number of key	
population in the catchment area)	
By key population type: Males who	
inject drugs (Male PWID)	
(Denominator: Total estimated	
number of key population in the	
catchment area)	
By key population type: Females	
who inject drugs (Female PWID)	
(Denominator: Total estimated	
number of key population in the	
catchment area)	
By key population type: Men who	
have sex with men and are sex	
workers (Numerator: Number of	
key populations reached with	
individual and/or small group level	289
HIV preventive interventions that	
are based on evidence and/or meet	
the minimum standards required)	
By key population type: Men who	
have sex with men and are NOT	
sex workers (Numerator: Number	
of key populations reached with	
individual and/or small group level	1,990
HIV preventive interventions that	
are based on evidence and/or meet	
the minimum standards required)	
By key population type:	



Transgender who are sex workers	
(Numerator: Number of key	
populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type:	
Transgender who are NOT sex	
workers (Numerator: Number of	
key populations reached with	
individual and/or small group level	221
HIV preventive interventions that	
are based on evidence and/or meet	
the minimum standards required)	
By key population type: Men who	
have sex with men and are sex	
workers (Denominator: Total	
estimated number of key	
population in the catchment area)	
By key population type: Men who	
have sex with men and are NOT	
sex workers (Denominator: Total	
estimated number of key	
population in the catchment area)	
By key population type:	
Transgender who are sex workers	
(Denominator: Total estimated	
number of key population in the	
catchment area)	
By key population type:	
Transgender who are NOT sex	
workers (Denominator: Total	
estimated number of key	
population in the catchment area)	
 By key population type: People in	



	prisons and enclosed settings	
	(Numerator: Number of key	
	populations reached with individual	
	and/or small group level HIV	
	preventive interventions that are	
	based on evidence and/or meet the	
	minimum standards required)	
	By key population type: People in	
	prisons and enclosed settings	
	(Denominator: Total estimated	
	number of key population in the	
	catchment area)	
	By Service: KP known positive	
	By Service: KP was tested as part	
	of the program and/or KP was	
	referred for testing as part of the	
	program	
	By New Client Status: New	
	beneficiary	
	By New Client Status: Returning	
	beneficiary within the current report	
	period	
	Number of individuals who received	
	T&C services for HIV and received	59,610
	their test results during the past 12	59,010
	months	
	Age/sex: 5-9 Male	
HTC_TST_DSD	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	



Age/sex: 15-19 Female
Age/sex: 20-24 Female
Age/sex: 25-49 Female
Age/sex: 50+ Female
Test Result by Age and Sex:
Positive: 10-14 Male
Test Result by Age and Sex:
Positive: 15-19 Male
Test Result by Age and Sex:
Positive: 20-24 Male
Test Result by Age and Sex:
Positive: 25-49 Male
Test Result by Age and Sex:
Positive: 50+ Male
Test Result by Age and Sex:
Positive: 10-14 Female
Test Result by Age and Sex:
Positive: 15-19 Female
Test Result by Age and Sex:
Positive: 20-24 Female
Test Result by Age and Sex:
Positive: 25-49 Female
Test Result by Age and Sex:
Positive: 50+ Female
Test Result by Age and Sex:
Negative: 10-14 Male
Test Result by Age and Sex:
Negative: 15-19 Male
Test Result by Age and Sex:
Negative: 20-24 Male
Test Result by Age and Sex:
Negative: 25-49 Male
Test Result by Age and Sex:
Negative: 50+ Male



۱	
Test Result by Age and Sex:	
Negative: 10-14 Female	
Test Result by Age and Sex:	
Negative: 15-19 Female	
Test Result by Age and Sex:	
Negative: 20-24 Female	
Test Result by Age and Sex:	
Negative: 25-49 Female	
Test Result by Age and Sex:	
Negative: 50+ Female	
Aggregated Age/sex - USE WITH	
HQ PERMISSION ONLY: <15 Male	
Aggregated Age/sex - USE WITH	
HQ PERMISSION ONLY: 15+ Male	47,776
Aggregated Age/sex - USE WITH	
HQ PERMISSION ONLY: <15	
Female	
Aggregated Age/sex - USE WITH	
HQ PERMISSION ONLY: 15+	11,833
Female	11,000
Test Result by Aggregated Age	
and Sex: Negative <15 Male	
Test Result by Aggregated Age	
and Sex: Negative 15+ Male	
Test Result by Aggregated Age	
and Sex: Negative <15 Female	
Test Result by Aggregated Age	
and Sex: Negative 15+ Female	
Test Result by Aggregated Age	
and Sex: Positive <15 Male	
Test Result by Aggregated Age	
and Sex: Positive 15+ Male	6,924
Test Result by Aggregated Age	
and Sex: Positive <15 Female	



	Test Result by Aggregated Age and Sex: Positive 15+ Female	938
	Test Result by Age: Positive: <1	
	Test Result by Age: Positive: 1-9	
	Age/sex: <1	
	Age/sex: 1-9	
	Service Delivery Point	
	(Community): Index testing	
	Service Delivery Point	
	(Community): Homebased testing	
	Service Delivery Point	
	(Community): Mobile testing	
	Service Delivery Point	
	(Community): Other	26,755
	Service Delivery Point (Community)	
	by Age: <15 index testing	
	Service Delivery Point (Community)	
	by Age: 15+ index testing	
	Service Delivery Point (Community)	
	by Age: <15 homebased testing	
	Service Delivery Point (Community)	
	by Age: 15+ homebased testing	
	Service Delivery Point (Community)	
	by Age: <15 mobile testing	
	Service Delivery Point (Community)	
	by Age: 15+ mobile testing	
	Service Delivery Point (Community)	
	by Age: <15 other	
	Service Delivery Point (Community)	
	by Age: <15 other	
	Service Delivery Point (Facility): Inpatient	
	Service Delivery Point (Facility):	
-	Outpatient	



Service Delivery Point (Facility): Pediatric	40
Service Delivery Point (Facility): Malnutrition facilities	
Service Delivery Point (Facility): Other PITC	
Service Delivery Point (Facility): VCT	1,940
Service Delivery Point (Facility): VMMC	
Service Delivery Point (Facility): PMTCT	
Service Delivery Point (Facility): TB Clinics	
Service Delivery Point (Facility): Index testing	
Service Delivery Point (Facility) by Age: <15 Inpatient	
Service Delivery Point (Facility) by Age: >15 Inpatient	
Service Delivery Point (Facility) by Age: <15 Outpatient	
Service Delivery Point (Facility) by Age: >15 Outpatient	
Service Delivery Point (Facility) by Age: <15 Pediatroc	
Service Delivery Point (Facility) by Age: >15 Pediatroc	
Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	
Service Delivery Point (Facility) by Age: <15 Other PITC	



	Service Delivery Point (Facility) by Age: >15 Other PITC	
	Service Delivery Point (Facility) by Age: <15 VCT	
	Service Delivery Point (Facility) by Age: >15 VCT	
	Service Delivery Point (Facility) by Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	520
	Age/sex: 5-9 Male	
HTC_TST_TA	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	



Age/sex: 15-19 Female
Age/sex: 20-24 Female
Age/sex: 25-49 Female
Age/sex: 50+ Female
Test Result by Age and Sex:
Positive: 10-14 Male
Test Result by Age and Sex:
Positive: 15-19 Male
Test Result by Age and Sex:
Positive: 20-24 Male
Test Result by Age and Sex:
Positive: 25-49 Male
Test Result by Age and Sex:
Positive: 50+ Male
Test Result by Age and Sex:
Positive: 10-14 Female
Test Result by Age and Sex:
Positive: 15-19 Female
Test Result by Age and Sex:
Positive: 20-24 Female
Test Result by Age and Sex:
Positive: 25-49 Female
Test Result by Age and Sex:
Positive: 50+ Female
Test Result by Age and Sex:
Negative: 10-14 Male
Test Result by Age and Sex:
Negative: 15-19 Male
Test Result by Age and Sex:
Negative: 20-24 Male
Test Result by Age and Sex:
Negative: 25-49 Male
Test Result by Age and Sex:
Negative: 50+ Male



1	
Test Result by Age and Sex:	
Negative: <1 Female	
Test Result by Age and Sex:	
Negative: 10-14 Female	
Test Result by Age and Sex:	
Negative: 15-19 Female	
Test Result by Age and Sex:	
Negative: 20-24 Female	
Test Result by Age and Sex:	
Negative: 25-49 Female	
Test Result by Age and Sex:	
Negative: 50+ Female	
Aggregated Age/sex - USE WITH	
HQ PERMISSION ONLY: <15 Male	
Aggregated Age/sex - USE WITH	
HQ PERMISSION ONLY: 15+ Male	520
Aggregated Age/sex - USE WITH	
HQ PERMISSION ONLY: <15	
Female	
Aggregated Age/sex - USE WITH	
HQ PERMISSION ONLY: 15+	
Female	
Test Result by Aggregated Age	
and Sex: Negative <15 Male	
Test Result by Aggregated Age	
and Sex: Negative 15+ Male	
Test Result by Aggregated Age	
and Sex: Negative <15 Female	
Test Result by Aggregated Age	
and Sex: Negative 15+ Female	
Test Result by Aggregated Age	
and Sex: Positive <15 Male	
Test Result by Aggregated Age	92
and Sex: Positive 15+ Male	92



Test Result by Aggregated Age
and Sex: Positive <15 Female
Test Result by Aggregated Age
and Sex: Positive 15+ Female
Test Result by Age: Positive: <1
Test Result by Age: Positive: 1-9
Age/sex: <1
Age/sex: 1-9
Service Delivery Point
(Community): Index testing
Service Delivery Point
(Community): Homebased testing
Service Delivery Point
(Community): Mobile testing
Service Delivery Point
(Community): Other
Service Delivery Point (Community)
by Age: <15 index testing
Service Delivery Point (Community)
by Age: 15+ index testing
Service Delivery Point (Community)
by Age: <15 homebased testing
Service Delivery Point (Community)
by Age: 15+ homebased testing
Service Delivery Point (Community)
by Age: <15 mobile testing
Service Delivery Point (Community)
by Age: 15+ mobile testing
Service Delivery Point (Community)
by Age: <15 other
Service Delivery Point (Community)
by Age: <15 other
Service Delivery Point (Facility):
Inpatient



Service Delivery Point (Facility): Outpatient	
Service Delivery Point (Facility): Pediatric	
Service Delivery Point (Facility): Malnutrition facilities	
Service Delivery Point (Facility): Other PITC	
Service Delivery Point (Facility): VCT	520
Service Delivery Point (Facility): VMMC	
Service Delivery Point (Facility): PMTCT	
Service Delivery Point (Facility): TB Clinics	
Service Delivery Point (Facility): Index testing	
Service Delivery Point (Facility) by Age: <15 Inpatient	
Service Delivery Point (Facility) by Age: >15 Inpatient	
Service Delivery Point (Facility) by Age: <15 Outpatient	
Service Delivery Point (Facility) by Age: >15 Outpatient	
Service Delivery Point (Facility) by Age: <15 Pediatroc	
Service Delivery Point (Facility) by Age: >15 Pediatroc	
Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	



	Service Delivery Point (Facility) by	
	Age: <15 Other PITC	
	Service Delivery Point (Facility) by	
	Age: >15 Other PITC	
	Service Delivery Point (Facility) by	
	Age: <15 VCT	
	Service Delivery Point (Facility) by	
	Age: >15 VCT	
	Service Delivery Point (Facility) by	
	Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by	
	Age: <15 TB Clinics	
	Service Delivery Point (Facility) by	
	Age: >15 TB Clinics	
	Service Delivery Point (Facility) by	
	Age: <15 Index testing	
	Service Delivery Point (Facility) by	
	Age: >15 Index testing	
	Number of adults and children	
	receiving antiretroviral therapy	3,900
	(ART)	
	Age/Sex: 15-19 Male	
TX_CURR_DSD	Age/Sex: 15-19 Female	
	Age/Sex: 20+ Female	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	
	Aggregated Age/Sex: 15+ Male	
L		



	Aggregated Age/Sex: <15 Female	
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	
	Sum of Aggregated Age/Sex <15	
	Sum of Aggregated Age/Sex 15+	
	Sum of Aggregated Age/Sex	
	disaggregates	
	Age/Sex: <1	
	Age/Sex: <1-9	
	Age/Sex: 10-14 Male	
	Age/Sex: 10-14 Female	
	Aggregated Age/Sex: 1-14 Male	
	Sum of Aggregated Age/Sex (<1	
	and 1-14) <15	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
	Number of adults and children	
	receiving antiretroviral therapy	6,625
	(ART)	
	Age/Sex: <1 Male	
TX_CURR_TA	Age/Sex: 1-4 Male	
	Age/Sex: 5-14 Male	
	Age/Sex: 15-19 Male	
	Age/Sex: 20+ Male	
	Age/Sex: <1 Female	
	Age/Sex: 1-4 Female	
	Age/Sex: 5-14 Female	
	Age/Sex: 15-19 Female	



	Age/Sex: 20+ Female	
	Sum of Age/Sex disaggregations	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	
	Aggregated Age/Sex: 1-14 Male	
	Aggregated Age/Sex: 15+ Male	3,377
	Aggregated Age/Sex: <15 Female	
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	3,248
	Sum of Aggregated Age/Sex <15	
	Sum of Aggregated Age/Sex 15+	6,625
	Sum of Aggregated Age/Sex disaggregates	6,625
	Age/Sex: <1	
	Age/Sex: 1-9	
	Age/Sex: 10-14 Male	
	Age/Sex: 10-14 Female	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
	Number of adults and children	
TX_NEW_DSD	newly enrolled on antiretroviral	2,284
	therapy (ART)	
	By Age/Sex: <1	
	By Age/Sex: 1-9	
	By Age/Sex: 10-14 Male	



	By Age/Sex: 15-19 Male	
	By Age/Sex: 20-24 Male	
	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	
	By Age/Sex: 20-24 Female	
	By Age/Sex: 25-49 Female	
	By Age/Sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <a><15 Male	
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	
	Aggregated Grouping by Age/Sex: <pre><1 Female</pre>	
	Aggregated Grouping by Age/Sex: <pre><15 Female</pre>	
	Aggregated Grouping by Age/Sex: 15+ Female	
	Sum of Aggregated Age/Sex disaggregates	
	Pregnancy status	
	Breastfeeding status	
	Aggregated Grouping by Age/Sex: 1-14 Female	
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral	5,055



therapy (ART)	
By Age/Sex: <1	
By Age/Sex: 1-9	
By Age/Sex: <1 Male	
By Age/Sex: 1-4 Male	
By Age/Sex: 5-9 Male	
By Age/Sex: 10-14 Male	
By Age/Sex: 15-19 Male	
By Age/Sex: 20-24 Male	
By Age/Sex: 25-49 Male	
By Age/Sex: 50+ Male	
By Age/Sex: <1 Female	
By Age/Sex: 1-4 Female	
By Age/Sex: 5-9 Female	
By Age/Sex: 10-14 Female	
By Age/Sex: 15-19 Female	
By Age/Sex: 20-24 Female	
By Age/Sex: 25-49 Female	
By Age/Sex: 50+ Female	
Sum of Age/Sex disaggregates	
Aggregated Grouping by Age: <1	
Aggregated Grouping by Age: <1 Male	
Aggregated Grouping by Age/Sex: <15 Male	
Aggregated Grouping by Age/Sex: 1-14 Male	
Aggregated Grouping by Age/Sex: 15+ Male	3,979
Aggregated Grouping by Age: <1 Female	
Aggregated Grouping by Age/Sex: <15 Female	



	Aggregated Grouping by Age/Sex: 1-14 Female	
	Aggregated Grouping by Age/Sex: 15+ Female	1,076
	Sum of Aggregated Age/Sex disaggregates	5,055
	Pregnancy status	
	Breastfeeding status	
LAB_PT_TA	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	
	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	12
	CD4: Number of laboratories that participate in this PT program	12
	CD4: Number of laboratories that perform this testing	
	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	
	Early infant diagnostics: Number of laboratories that participate in this PT program	
	Early infant diagnostics: Number of laboratories that perform this testing	
	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	42



	HIV serologic/diagnostic testing:	
	Number of laboratories that	42
	participate in this PT program	
	HIV serologic/diagnostic testing:	
	Number of laboratories that	
	perform this testing	
	HIV viral load: Number of	
	laboratories that achieve	10
i	acceptable successful passing	12
	criteria in this PT program	
	HIV viral load: Number of	
	laboratories that participate in this	12
	PT program	
	HIV viral load: Number of	
	laboratories that perform this	
	testing	
	TB diagnostics (AFB microscopy):	
	Number of laboratories that	
	achieve acceptable successful	
	passing criteria in this PT program	
	TB diagnostics (AFB microscopy):	
	Number of laboratories that	
	participate in this PT program	
	TB diagnostics (AFB microscopy):	
	Number of laboratories that	
	perform this testing	
	TB diagnostics (Xpert MTB/RIF):	
	Number of laboratories that	
	achieve acceptable successful	
	passing criteria in this PT program	
	TB diagnostics (Xpert MTB/RIF):	
	Number of laboratories that	
	participate in this PT program	
	B diagnostics (Xpert MTB/RIF):	
	Number of laboratories that	



		1
	perform this testing	
	TB diagnostics (Culture/DST):	
	Number of laboratories that	
	achieve acceptable successful	
	passing criteria in this PT program	
	TB diagnostics (Culture/DST):	
	Number of laboratories that	
	participate in this PT program	
	TB diagnostics (Culture/DST):	
	Number of laboratories that	
	perform this testing	
	Number of new HCW who	
	graduated from a pre-service	
	training institution or program as a	230
	result of PEPFAR-supported	230
	strengthening efforts, within the	
	reporting period, by select cadre	
	By Graduates: Doctors	
HRH_PRE	By Graduates: Nurses	
	By Graduates: Midwives	
	By Graduates: Social service	
	workers	
	By Graduates: Laboratory	
	professionals	
	By Graduates: Other	
	Sum of Graduates disaggreagtes	



Technical Area Summary Indicators and Targets

Asia Regional Program

Indicator Number	Label	2017
KP_MAT_TA	KP_MAT_TA Percentage of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	n/a
	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	6,976
	Sex: Female	698
	Sex: Male	6,278
	Sum of Sex Disaggregates	6,976
	PrEP_NEW_DSD Number of individuals who have received antiretroviral pre-exposure prophylaxis (PrEP) to prevent HIV infection in the reporting period.	n/a
	Number of individuals who have received antiretroviral preexposure	750
	Male 10-14	
PrEP_NEW_DSD	Male 15-19	
	Male 20-24	
	Male 25-49	
	Male 50+	
	Female 10-14	
	Female 15-19	
	Female 20-24	
	Female 25-49	
	Female 50+	



	1	
	PrEP_NEW_TA Number of adult	
	women and adolecent girls newly	n/a
	enrolled on oral or topical PrEP	
	Number of adult women and	
	adolecent girls newly enrolled on	621
	oral or topical PrEP	
	Male 10-14	
	Male 15-19	
PrEP_NEW_TA	Male 20-24	580
	Male 25-49	
	Male 50+	
	Female 10-14	
	Female 15-19	
	Female 20-24	41
	Female 25-49	
	Female 50+	
	KP_PREV_DSD Percentage of key	
	populations reached with individual	
	and/or small group level HIV	- 1-
	preventive interventions that are	n/a
	based on evidence and/or meet the	
	minimum standards required (DSD)	
	Number of key populations reached	
	with individual and/or small group	
	level HIV preventive interventions	87,003
	that are based on evidence and/or	07,003
	meet the minimum standards	
	required	
	Total estimated number of key	
	population in the catchment area	
	By key population type: Men who	
	have sex with men who are sex	
	workers (Numerator: Number of	
	key populations reached with	



individual and/or small group level	
HIV preventive interventions that	
are based on evidence and/or meet	
the minimum standards required)	
By key population type: Men who	
have sex with men who are NOT	
sex workers (Numerator: Number	
of key populations reached with	
individual and/or small group level	
HIV preventive interventions that	
are based on evidence and/or meet	
the minimum standards required)	
By key population type:	
Transgender who are sex workers	
(Numerator: Number of key	
populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type:	
Transgender who are NOT sex	
workers (Numerator: Number of	
key populations reached with	
individual and/or small group level	
HIV preventive interventions that	
are based on evidence and/or meet	
the minimum standards required)	
By key population type: Female	
sex workers (FSW) (Numerator:	
Number of key populations reached	
with individual and/or small group	
level HIV preventive interventions	
that are based on evidence and/or	
meet the minimum standards	
required)	



By key population type: Males who
inject drugs (Male PWID)
(Numerator: Number of key
populations reached with individual
and/or small group level HIV
preventive interventions that are
based on evidence and/or meet the
minimum standards required)
By key population type: Females
who inject drugs (Female PWID)
(Numerator: Number of key
populations reached with individual
and/or small group level HIV
preventive interventions that are
based on evidence and/or meet the
minimum standards required)
By key population type: People in
prisons and enclosed settings
(Numerator: Number of key
populations reached with individual
and/or small group level HIV
preventive interventions that are
based on evidence and/or meet the
minimum standards required)
By key population type: Men who
have sex with men who are sex
workers (Denominator: Total
estimated number of key
population in the catchment area
By key population type: Men who
have sex with men who are NOT
sex workers (Denominator: Total
estimated number of key
population in the catchment area)
By key population type:
Transgender who are sex workers
TRUSYCHUCK WITH ALE SEA WULKETS



(Denominator: Total estimated
number of key population in the
catchment area)
By key population type:
Transgender who are NOT sex
workers (Denominator: Total
estimated number of key
population in the catchment area)
By key population type: Female
sex workers (FSW) (Denominator:
Total estimated number of key
population in the catchment area)
By key population type: Males who
inject drugs (Male PWID)
(Denominator: Total estimated
number of key population in the
catchment area)
By key population type: Females
who inject drugs (Female PWID)
(Denominator: Total estimated
number of key population in the
catchment area)
By key population type: People in
prisons and enclosed settings
(Denominator: Total estimated
number of key population in the
catchment area)
By Service: KP known status
By Service: KP was tested as part
of the program and/or KP was
referred for testing as part of the
program
By New Client Status: New
beneficiary
By New Client Status: REturniong



	beneficiary within the current report	
	KP_PREV_TA Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (TA-only)	n/a
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	22,871
	Total estimated number of key population in the catchment area	138,571
KP_PREV_TA	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key	



populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type: Female	
sex workers (FSW) (Denominator:	
Total estimated number of key	
population in the catchment area)	
By key population type: Males who	
inject drugs (Male PWID)	
(Denominator: Total estimated	
number of key population in the	
catchment area)	
By key population type: Females	
who inject drugs (Female PWID)	
(Denominator: Total estimated	
number of key population in the	
catchment area)	
By key population type: Men who	
have sex with men and are sex	
workers (Numerator: Number of	
key populations reached with	
individual and/or small group level	289
HIV preventive interventions that	
are based on evidence and/or meet	
the minimum standards required)	
By key population type: Men who have sex with men and are NOT	
sex workers (Numerator: Number	
of key populations reached with	22,361
individual and/or small group level	
HIV preventive interventions that	
are based on evidence and/or meet	
the minimum standards required)	
By key population type:	



	Transgender who are sex workers	
	(Numerator: Number of key	
	populations reached with individual	
a	nd/or small group level HIV	
r	preventive interventions that are	
	based on evidence and/or meet the	
	minimum standards required)	
E	By key population type:	
ŀ	Transgender who are NOT sex	
,	workers (Numerator: Number of	
	key populations reached with	004
1	individual and/or small group level	221
	HIV preventive interventions that	
	are based on evidence and/or meet	
t	he minimum standards required)	
	By key population type: Men who	
	have sex with men and are sex	
,	workers (Denominator: Total	
	estimated number of key	
	population in the catchment area)	
Ī	By key population type: Men who	
	have sex with men and are NOT	
	sex workers (Denominator: Total	138,571
	estimated number of key	
	population in the catchment area)	
	By key population type:	
	Transgender who are sex workers	
	(Denominator: Total estimated	
	number of key population in the	
	catchment area)	
Ē		
	By key population type:	
	Transgender who are NOT sex	
	workers (Denominator: Total	
	estimated number of key	
-	opulation in the catchment area)	
E	By key population type: People in	



	prisons and enclosed settings	
	(Numerator: Number of key	
	populations reached with individual	
	and/or small group level HIV	
	preventive interventions that are	
	based on evidence and/or meet the	
	minimum standards required)	
	By key population type: People in	
	prisons and enclosed settings	
	(Denominator: Total estimated	
	number of key population in the	
	catchment area)	
	By Service: KP known positive	
	By Service: KP was tested as part	
	of the program and/or KP was	
	referred for testing as part of the	
	program	
	By New Client Status: New	
	beneficiary	
	By New Client Status: Returning	
	beneficiary within the current report	
	period	
	Number of individuals who received	
	T&C services for HIV and received	62,252
	their test results during the past 12	02,232
	months	
	Age/sex: 5-9 Male	
HTC_TST_DSD	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	



Age/sex: 15-19 Female
Age/sex: 20-24 Female
Age/sex: 25-49 Female
Age/sex: 50+ Female
Test Result by Age and Sex:
Positive: 10-14 Male
Test Result by Age and Sex:
Positive: 15-19 Male
Test Result by Age and Sex:
Positive: 20-24 Male
Test Result by Age and Sex:
Positive: 25-49 Male
Test Result by Age and Sex:
Positive: 50+ Male
Test Result by Age and Sex:
Positive: 10-14 Female
Test Result by Age and Sex:
Positive: 15-19 Female
Test Result by Age and Sex:
Positive: 20-24 Female
Test Result by Age and Sex:
Positive: 25-49 Female
Test Result by Age and Sex:
Positive: 50+ Female
Test Result by Age and Sex:
Negative: 10-14 Male
Test Result by Age and Sex:
Negative: 15-19 Male
Test Result by Age and Sex:
Negative: 20-24 Male
Test Result by Age and Sex:
Negative: 25-49 Male
Test Result by Age and Sex:
Negative: 50+ Male



-	Test Result by Age and Sex:	
1	Negative: 10-14 Female	
-	Test Result by Age and Sex:	
1	Negative: 15-19 Female	
-	Test Result by Age and Sex:	
1	Negative: 20-24 Female	
-	Test Result by Age and Sex:	
1	Negative: 25-49 Female	
-	Test Result by Age and Sex:	
1	Negative: 50+ Female	
/	Aggregated Age/sex - USE WITH	18
ł	HQ PERMISSION ONLY: <15 Male	10
ļ	Aggregated Age/sex - USE WITH	49,634
ł	HQ PERMISSION ONLY: 15+ Male	43,004
/	Aggregated Age/sex - USE WITH	
ł	HQ PERMISSION ONLY: <15	24
F	Female	
/	Aggregated Age/sex - USE WITH	
	HQ PERMISSION ONLY: 15+	12,575
F	Female	
-	Test Result by Aggregated Age	
ć	and Sex: Negative <15 Male	
-	Test Result by Aggregated Age	
ć	and Sex: Negative 15+ Male	
-	Test Result by Aggregated Age	
ć	and Sex: Negative <15 Female	
-	Test Result by Aggregated Age	
ć	and Sex: Negative 15+ Female	
ŀ	Test Result by Aggregated Age	0
ć	and Sex: Positive <15 Male	U
-	Test Result by Aggregated Age	7 204
2	and Sex: Positive 15+ Male	7,394
ŀ	Test Result by Aggregated Age	F
a	nd Sex: Positive <15 Female	5



Test Result by Aggregated Age and Sex: Positive 15+ Female	1,134
Test Result by Age: Positive: <1	
Test Result by Age: Positive: 1-9	
Age/sex: <1	
Age/sex: 1-9	
Service Delivery Point (Community): Index testing	635
Service Delivery Point (Community): Homebased testing	0
Service Delivery Point (Community): Mobile testing	0
Service Delivery Point (Community): Other	27,688
Service Delivery Point (Community) by Age: <15 index testing	
Service Delivery Point (Community) by Age: 15+ index testing	
Service Delivery Point (Community) by Age: <15 homebased testing	
Service Delivery Point (Community) by Age: 15+ homebased testing	
Service Delivery Point (Community) by Age: <15 mobile testing	
Service Delivery Point (Community) by Age: 15+ mobile testing	
Service Delivery Point (Community) by Age: <15 other	
Service Delivery Point (Community) by Age: <15 other	
Service Delivery Point (Facility): Inpatient	
Service Delivery Point (Facility): Outpatient	



Service Delivery Point (Facility): Pediatric	40
Service Delivery Point (Facility): Malnutrition facilities	
Service Delivery Point (Facility): Other PITC	
Service Delivery Point (Facility): VCT	1,975
Service Delivery Point (Facility): VMMC	
Service Delivery Point (Facility): PMTCT	
Service Delivery Point (Facility): TB Clinics	
Service Delivery Point (Facility): Index testing	15
Service Delivery Point (Facility) by Age: <15 Inpatient	
Service Delivery Point (Facility) by Age: >15 Inpatient	
Service Delivery Point (Facility) by Age: <15 Outpatient	
Service Delivery Point (Facility) by Age: >15 Outpatient	
Service Delivery Point (Facility) by Age: <15 Pediatroc	
Service Delivery Point (Facility) by Age: >15 Pediatroc	
Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	
Service Delivery Point (Facility) by Age: <15 Other PITC	



	Service Delivery Point (Facility) by Age: >15 Other PITC	
	Service Delivery Point (Facility) by Age: <15 VCT	
	Service Delivery Point (Facility) by Age: >15 VCT	
	Service Delivery Point (Facility) by Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	15,458
HTC_TST_TA	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	

Page 105 of 165



Age/sex: 15-19 Female
Age/sex: 20-24 Female
Age/sex: 25-49 Female
Age/sex: 50+ Female
Test Result by Age and Sex:
Positive: 10-14 Male
Test Result by Age and Sex:
Positive: 15-19 Male
Test Result by Age and Sex:
Positive: 20-24 Male
Test Result by Age and Sex:
Positive: 25-49 Male
Test Result by Age and Sex:
Positive: 50+ Male
Test Result by Age and Sex:
Positive: 10-14 Female
Test Result by Age and Sex:
Positive: 15-19 Female
Test Result by Age and Sex:
Positive: 20-24 Female
Test Result by Age and Sex:
Positive: 25-49 Female
Test Result by Age and Sex:
Positive: 50+ Female
Test Result by Age and Sex:
Negative: 10-14 Male
Test Result by Age and Sex:
Negative: 15-19 Male
Test Result by Age and Sex:
Negative: 20-24 Male
Test Result by Age and Sex:
Negative: 25-49 Male
Test Result by Age and Sex:
Negative: 50+ Male



Test Result by Age and Sex: Negative: <1 Female	
Test Result by Age and Sex:	
Negative: 10-14 Female	
Test Result by Age and Sex:	
Negative: 15-19 Female	
Test Result by Age and Sex:	
Negative: 20-24 Female	
Test Result by Age and Sex:	
Negative: 25-49 Female	
Test Result by Age and Sex:	
Negative: 50+ Female	
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	
Aggregated Age/sex - USE WITH	
HQ PERMISSION ONLY: 15+ Male	15,458
Aggregated Age/sex - USE WITH	
HQ PERMISSION ONLY: <15	
Female	
Aggregated Age/sex - USE WITH	
HQ PERMISSION ONLY: 15+	
Female	
Test Result by Aggregated Age	
and Sex: Negative <15 Male	
Test Result by Aggregated Age	
and Sex: Negative 15+ Male	
Test Result by Aggregated Age	
and Sex: Negative <15 Female	
Test Result by Aggregated Age	
and Sex: Negative 15+ Female	
Test Result by Aggregated Age and Sex: Positive <15 Male	
Test Result by Aggregated Age	
and Sex: Positive 15+ Male	1,086



Test Result by Aggregated Age and Sex: Positive <15 Female	
Test Result by Aggregated Age and Sex: Positive 15+ Female	
Test Result by Age: Positive: <1	
Test Result by Age: Positive: 1-9	
Age/sex: <1	
Age/sex: 1-9	
Service Delivery Point	11,900
(Community): Index testing	
Service Delivery Point	
(Community): Homebased testing	
Service Delivery Point	
(Community): Mobile testing	
Service Delivery Point	
(Community): Other	
Service Delivery Point (Community)	
by Age: <15 index testing	
Service Delivery Point (Community)	
by Age: 15+ index testing	
Service Delivery Point (Community)	
by Age: <15 homebased testing	
Service Delivery Point (Community)	
by Age: 15+ homebased testing	
Service Delivery Point (Community)	
by Age: <15 mobile testing	
Service Delivery Point (Community)	
by Age: 15+ mobile testing	
Service Delivery Point (Community)	
by Age: <15 other	
Service Delivery Point (Community)	
by Age: <15 other	
Service Delivery Point (Facility):	
Inpatient	
•	



Service Delivery Point (Facility): Outpatient	
Service Delivery Point (Facility): Pediatric	
Service Delivery Point (Facility): Malnutrition facilities	
Service Delivery Point (Facility): Other PITC	
Service Delivery Point (Facility): VCT	1,170
Service Delivery Point (Facility): VMMC	
Service Delivery Point (Facility): PMTCT	
Service Delivery Point (Facility): TB Clinics	
Service Delivery Point (Facility): Index testing	
Service Delivery Point (Facility) by Age: <15 Inpatient	
Service Delivery Point (Facility) by Age: >15 Inpatient	
Service Delivery Point (Facility) by Age: <15 Outpatient	
Service Delivery Point (Facility) by Age: >15 Outpatient	
Service Delivery Point (Facility) by Age: <15 Pediatroc	
Service Delivery Point (Facility) by Age: >15 Pediatroc	
Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	



	Service Delivery Point (Facility) by	
	Age: <15 Other PITC	
	Service Delivery Point (Facility) by	
	Age: >15 Other PITC	
	Service Delivery Point (Facility) by	
	Age: <15 VCT	
	Service Delivery Point (Facility) by Age: >15 VCT	
	Service Delivery Point (Facility) by Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by	
	Age: >15 Index testing	
	Number of adults and children	
	receiving antiretroviral therapy (ART)	4,290
TX_CURR_DSD	Age/Sex: 15-19 Male	
	Age/Sex: 15-19 Female	
	Age/Sex: 20+ Female	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	1
	Aggregated Age/Sex: 15+ Male	219
	·	



	Aggregated Age/Sex: <15 Female	0
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	170
	Sum of Aggregated Age/Sex <15	1
	Sum of Aggregated Age/Sex 15+	389
	Sum of Aggregated Age/Sex disaggregates	390
	Age/Sex: <1	
	Age/Sex: <1-9	
	Age/Sex: 10-14 Male	
	Age/Sex: 10-14 Female	
	Aggregated Age/Sex: 1-14 Male	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
	Number of adults and children receiving antiretroviral therapy (ART)	9,020
TX_CURR_TA	Age/Sex: <1 Male	
	Age/Sex: 1-4 Male	
	Age/Sex: 5-14 Male	
	Age/Sex: 15-19 Male	
	Age/Sex: 20+ Male	
	Age/Sex: <1 Female	
	Age/Sex: 1-4 Female	
	Age/Sex: 5-14 Female	
	Age/Sex: 15-19 Female	



	Age/Sex: 20+ Female	
	Sum of Age/Sex disaggregations	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	68
	Aggregated Age/Sex: 1-14 Male	
	Aggregated Age/Sex: 15+ Male	4,486
	Aggregated Age/Sex: <15 Female	74
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	4,290
	Sum of Aggregated Age/Sex <15	142
	Sum of Aggregated Age/Sex 15+	8,776
	Sum of Aggregated Age/Sex disaggregates	8,918
	Age/Sex: <1	
	Age/Sex: 1-9	
	Age/Sex: 10-14 Male	
	Age/Sex: 10-14 Female	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
	Number of adults and children	
TX_NEW_DSD	newly enrolled on antiretroviral	2,344
	therapy (ART)	
	By Age/Sex: <1	
	By Age/Sex: 1-9	
	By Age/Sex: 10-14 Male	



	By Age/Sex: 15-19 Male	
	By Age/Sex: 20-24 Male	
	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	
	By Age/Sex: 20-24 Female	
	By Age/Sex: 25-49 Female	
	By Age/Sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <a><15 Male	0
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	42
	Aggregated Grouping by Age/Sex: <1 Female	
	Aggregated Grouping by Age/Sex: <pre><15 Female</pre>	0
	Aggregated Grouping by Age/Sex: 15+ Female	18
	Sum of Aggregated Age/Sex disaggregates	60
	Pregnancy status	
	Breastfeeding status	
	Aggregated Grouping by Age/Sex: 1-14 Female	
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral	5,672



therapy (ART)	
By Age/Sex: <1	
By Age/Sex: 1-9	
By Age/Sex: <1 Male	
By Age/Sex: 1-4 Male	
By Age/Sex: 5-9 Male	
By Age/Sex: 10-14 Male	
By Age/Sex: 15-19 Male	
By Age/Sex: 20-24 Male	
By Age/Sex: 25-49 Male	
By Age/Sex: 50+ Male	
By Age/Sex: <1 Female	
By Age/Sex: 1-4 Female	
By Age/Sex: 5-9 Female	
By Age/Sex: 10-14 Female	
By Age/Sex: 15-19 Female	
By Age/Sex: 20-24 Female	
By Age/Sex: 25-49 Female	
By Age/Sex: 50+ Female	
Sum of Age/Sex disaggregates	
Aggregated Grouping by Age: <1	
Aggregated Grouping by Age: <1 Male	
Aggregated Grouping by Age/Sex: <pre><15 Male</pre>	17
Aggregated Grouping by Age/Sex: 1-14 Male	
Aggregated Grouping by Age/Sex: 15+ Male	4,201
Aggregated Grouping by Age: <1 Female	
Aggregated Grouping by Age/Sex: <15 Female	19



	Aggregated Grouping by Age/Sex: 1-14 Female	
	Aggregated Grouping by Age/Sex: 15+ Female	1,366
	Sum of Aggregated Age/Sex disaggregates	5,603
	Pregnancy status	
	Breastfeeding status	
	TX_PVLS_DSD Percentage of ART patients with a viral load result	
	documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	n/a
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	268
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	287
	Numerator: Indication: Routine	268
	Numerator: Indication: Targeted	0
	Numerator: Preg/BF by Indication: Pregnant Routine	
	Numerator: Preg/BF by Indication: Breastfeeding Routine	
	Numerator: Preg/BF by Indication: Pregnant Targeted	
	Numerator: Preg/BF by Indication:	



1	
Breastfeeding Targeted	
Numerator: Age/Sex by Indication:	
<1 Routine	
Numerator: Age/Sex by Indication:	
1-9 Routine	
Numerator: Age/Sex by Indication:	
10-14 Male Routine	
Numerator: Age/Sex by Indication:	
15-19 Male Routine	
Numerator: Age/Sex by Indication:	
20-24 Male Routine	
Numerator: Age/Sex by Indication:	
25-49 Male Routine	
Numerator: Age/Sex by Indication:	
50+ Male Routine	
Numerator: Age/Sex by Indication:	
10-14 Female Routine	
Numerator: Age/Sex by Indication:	
15-19 Female Routine	
Numerator: Age/Sex by Indication:	
20-24 Female Routine	
Numerator: Age/Sex by Indication:	
25-49 Female Routine	
Numerator: Age/Sex by Indication:	
50+ Female Routine	
Numerator: Age/Sex by Indication:	
<1 Targeted	
Numerator: Age/Sex by Indication:	
1-9 Targeted	
Numerator: Age/Sex by Indication:	
10-14 Male Targeted	
Numerator: Age/Sex by Indication:	
15-19 Male Targeted	
Numerator: Age/Sex by Indication:	



20-24 Male Targeted	
Numerator: Age/Sex by Indication:	
25-49 Male Targeted	
Numerator: Age/Sex by Indication:	
50+ Male Targeted	
Numerator: Age/Sex by Indication:	
10-14 Female Targeted	
Numerator: Age/Sex by Indication:	
15-19 Female Targeted	
Numerator: Age/Sex by Indication:	
20-24 Female Targeted	
Numerator: Age/Sex by Indication:	
25-49 Female Targeted	
Numerator: Age/Sex by Indication:	
50+ Female Targeted	
Numerator: Aggregate Age/Sex by	
Indication: <15 Male Targeted	
Numerator: Aggregate Age/Sex by	
Indication: 15+ Male Targeted	
Numerator: Aggregate Age/Sex by	
Indication: <15 Female Targeted	
Numerator: Aggregate Age/Sex by	
Indication: 15+ Female Targeted	
Numerator: Aggregate Age/Sex by	
Indication: <15 Male Routine	
Numerator: Aggregate Age/Sex by	
Indication: 15+ Male Routine	
Numerator: Aggregate Age/Sex by	
Indication: <15 Female Routine	
Numerator: Aggregate Age/Sex by	
Indication: 15+ Female Routine	
Denominator: Indication: Routine	287
Denominator: Indication: Targeted	0
Denominator: Preg/BF by	



Indication: Pregnant Routine	
Denominator: Preg/BF by	
Indication: Breastfeeding Routine	
Denominator: Preg/BF by	
Indication: Pregnant Targeted	
Denominator: Preg/BF by	
Indication: Breastfeeding Targeted	
Denominator: Age/Sex by	
Indication: <1 Routine	
Denominator: Age/Sex by	
Indication: 1-9 Routine	
Denominator: Age/Sex by	
Indication: 10-14 Male Routine	
Denominator: Age/Sex by	
Indication: 15-19 Male Routine	
Denominator: Age/Sex by	
Indication: 20-24 Male Routine	
Denominator: Age/Sex by	
Indication: 25-49 Male Routine	
Denominator: Age/Sex by	
Indication: 50+ Male Routine	
Denominator: Age/Sex by	
Indication: 10-14 Female Routine	
Denominator: Age/Sex by	
Indication: 15-19 Female Routine	
Denominator: Age/Sex by	
Indication: 20-24 Female Routine	
Denominator: Age/Sex by	
Indication: 25-49 Female Routine	
Denominator: Age/Sex by	
Indication: 50+ Female Routine	
Denominator: Age/Sex by	
Indication: <1 Targeted	
Denominator: Age/Sex by	



Indication: 1-9 Targeted Denominator: Age/Sex by Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 15-19 Male Targeted Denominator: Age/Sex by Indication: 20-24 Male Targeted Denominator: Age/Sex by Indication: 25-49 Male Targeted Denominator: Age/Sex by Indication: 25-49 Male Targeted Denominator: Age/Sex by Indication: 50+ Male Targeted Denominator: Age/Sex by Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 25-9 Female Targeted Denominator: Age/Sex by Indication: 25-9 Female Targeted Denominator: Age/Sex by Indication: 25-9 Female Targeted Denominator: Age/Sex by Indication: 26-9 Female Targeted Denominator: Age/Sex by Indication: 15-19 Female Targeted Denominator: Age/Sex by Indication: 15-19 Female Targeted Denominator: Agergate Age/Sex by Indication: 15+ Male Targeted Denominator: Aggregate Age/Sex by Indication:	
Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 15-19 Male Targeted Denominator: Age/Sex by Indication: 20-24 Male Targeted Denominator: Age/Sex by Indication: 25-49 Male Targeted Denominator: Age/Sex by Indication: 50+ Male Targeted Denominator: Age/Sex by Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 15-19 Female Targeted Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 50+ Female Targeted Denominator: Age/Sex by Indication: 50+ Female Targeted Denominator: Age/Sex by Indication: 51+ Female Targeted Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	Indication: 1-9 Targeted
Denominator: Age/Sex by Indication: 15-19 Male Targeted Denominator: Age/Sex by Indication: 20-24 Male Targeted Denominator: Age/Sex by Indication: 25-49 Male Targeted Denominator: Age/Sex by Indication: 50+ Male Targeted Denominator: Age/Sex by Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 15-19 Female Targeted Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 25-49 Female Targeted Denominator: Age/Sex by Indication: 50+ Female Targeted Denominator: Age/Sex by Indication: 50+ Female Targeted Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted Denominator: Aggregate Age/Sex by Indication: 15 Female Targeted Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	Denominator: Age/Sex by
Indication: 15-19 Male Targeted Denominator: Age/Sex by Indication: 20-24 Male Targeted Denominator: Age/Sex by Indication: 25-49 Male Targeted Denominator: Age/Sex by Indication: 50+ Male Targeted Denominator: Age/Sex by Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 15-19 Female Targeted Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 25-49 Female Targeted Denominator: Age/Sex by Indication: 50+ Female Targeted Denominator: Age/Sex by Indication: 50+ Female Targeted Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	Indication: 10-14 Male Targeted
Denominator: Age/Sex by Indication: 20-24 Male Targeted Denominator: Age/Sex by Indication: 25-49 Male Targeted Denominator: Age/Sex by Indication: 50+ Male Targeted Denominator: Age/Sex by Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 15-19 Female Targeted Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 25-49 Female Targeted Denominator: Age/Sex by Indication: 25-49 Female Targeted Denominator: Age/Sex by Indication: 25-49 Female Targeted Denominator: Age/Sex by Indication: 30+ Female Targeted Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	Denominator: Age/Sex by
Indication: 20-24 Male Targeted Denominator: Age/Sex by Indication: 25-49 Male Targeted Denominator: Age/Sex by Indication: 50+ Male Targeted Denominator: Age/Sex by Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 15-19 Female Targeted Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 25-49 Female Targeted Denominator: Age/Sex by Indication: 50+ Female Targeted Denominator: Age/Sex by Indication: 50+ Female Targeted Denominator: Age/Sex by Indication: 50+ Female Targeted Denominator: Aggregate Age/Sex by Indication: 15- Male Targeted Denominator: Aggregate Age/Sex by Indication: 15- Female Targeted Denominator: Aggregate Age/Sex by Indication: 15- Female Targeted Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	Indication: 15-19 Male Targeted
Denominator: Age/Sex by Indication: 25-49 Male Targeted Denominator: Age/Sex by Indication: 50+ Male Targeted Denominator: Age/Sex by Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 15-19 Female Targeted Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 25-49 Female Targeted Denominator: Age/Sex by Indication: 50+ Female Targeted Denominator: Age/Sex by Indication: 50+ Female Targeted Denominator: Agergate Age/Sex by Indication: <15 Male Targeted	Denominator: Age/Sex by
Indication: 25-49 Male Targeted Denominator: Age/Sex by Indication: 50+ Male Targeted Denominator: Age/Sex by Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 15-19 Female Targeted Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 25-49 Female Targeted Denominator: Age/Sex by Indication: 50+ Female Targeted Denominator: Agergate Age/Sex by Indication: 15 Male Targeted Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	Indication: 20-24 Male Targeted
Denominator: Aggregate Agg/Sex by Indication: 15+ Male Targeted Denominator: Aggregate Agg/Sex by Indication: 15-15 Female Targeted Denominator: Aggregate Agg/Sex by Indication: 20-24 Female Targeted Denominator: Aggregate Agg/Sex by Indication: 50+ Female Targeted Denominator: Aggregate Agg/Sex by Indication: 15+ Male Targeted Denominator: Aggregate Agg/Sex by Indication: 15+ Female Targeted	Denominator: Age/Sex by
Indication: 50+ Male Targeted Denominator: Age/Sex by Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 15-19 Female Targeted Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 25-49 Female Targeted Denominator: Age/Sex by Indication: 50+ Female Targeted Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted Denominator: Aggregate Age/Sex by Indication: <15+ Male Routine Denominator: Aggregate Age/Sex by Indication: <15+ Male Routine	Indication: 25-49 Male Targeted
Denominator: Age/Sex by Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 15-19 Female Targeted Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 25-49 Female Targeted Denominator: Age/Sex by Indication: 50+ Female Targeted Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted Denominator: Aggregate Age/Sex by Indication: <15 Male Routine Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	Denominator: Age/Sex by
Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 15-19 Female Targeted Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 25-49 Female Targeted Denominator: Age/Sex by Indication: 25-49 Female Targeted Denominator: Age/Sex by Indication: 50+ Female Targeted Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	Indication: 50+ Male Targeted
Denominator: Age/Sex by Indication: 15-19 Female Targeted Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 25-49 Female Targeted Denominator: Age/Sex by Indication: 50+ Female Targeted Denominator: Age/Sex by Indication: 50+ Female Targeted Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	Denominator: Age/Sex by
Indication: 15-19 Female Targeted Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 25-49 Female Targeted Denominator: Age/Sex by Indication: 50+ Female Targeted Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted Denominator: Aggregate Age/Sex by Indication: <15 Hale Routine Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	Indication: 10-14 Female Targeted
Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 25-49 Female Targeted Denominator: Age/Sex by Indication: 50+ Female Targeted Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted Denominator: Aggregate Age/Sex by Indication: <15 Male Routine Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	Denominator: Age/Sex by
Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 25-49 Female Targeted Denominator: Age/Sex by Indication: 50+ Female Targeted Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted Denominator: Aggregate Age/Sex by Indication: <15 Male Routine Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	Indication: 15-19 Female Targeted
Denominator: Age/Sex by Indication: 25-49 Female Targeted Denominator: Age/Sex by Indication: 50+ Female Targeted Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted Denominator: Aggregate Age/Sex by Indication: <15 Male Routine Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	Denominator: Age/Sex by
Indication: 25-49 Female Targeted Denominator: Age/Sex by Indication: 50+ Female Targeted Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted Denominator: Aggregate Age/Sex by Indication: <15 Male Routine Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	Indication: 20-24 Female Targeted
Denominator: Age/Sex by Indication: 50+ Female Targeted Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted Denominator: Aggregate Age/Sex by Indication: <15 Hale Routine Denominator: Aggregate Age/Sex by Indication: <15 Male Routine Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	Denominator: Age/Sex by
Indication: 50+ Female Targeted Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	Indication: 25-49 Female Targeted
Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted Denominator: Aggregate Age/Sex by Indication: <15 Hale Routine Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	Denominator: Age/Sex by
by Indication: <15 Male Targeted Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted Denominator: Aggregate Age/Sex by Indication: <15 Male Routine Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	Indication: 50+ Female Targeted
Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted Denominator: Aggregate Age/Sex by Indication: <15 Male Routine Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	Denominator: Aggregate Age/Sex
by Indication: 15+ Male Targeted Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted Denominator: Aggregate Age/Sex by Indication: <15 Male Routine Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	by Indication: <15 Male Targeted
Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted Denominator: Aggregate Age/Sex by Indication: <15 Male Routine Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	Denominator: Aggregate Age/Sex
by Indication: <15 Female Targeted Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted Denominator: Aggregate Age/Sex by Indication: <15 Male Routine Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	by Indication: 15+ Male Targeted
Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted Denominator: Aggregate Age/Sex by Indication: <15 Male Routine Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	Denominator: Aggregate Age/Sex
by Indication: 15+ Female Targeted Denominator: Aggregate Age/Sex by Indication: <15 Male Routine Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	by Indication: <15 Female Targeted
Denominator: Aggregate Age/Sex by Indication: <15 Male Routine Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	Denominator: Aggregate Age/Sex
by Indication: <15 Male Routine Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	by Indication: 15+ Female Targeted
Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	Denominator: Aggregate Age/Sex
by Indication: 15+ Male Routine	by Indication: <15 Male Routine
by Indication: 15+ Male Routine	Denominator: Aggregate Age/Sex
Denominator: Aggregate Age/Sex	
	Denominator: Aggregate Age/Sex



	by Indication: <15 Female Routine	
	Denominator: Aggregate Age/Sex	
	by Indication: 15+ Female Routine	
	Numerator Aggregated Age/Sex: <pre><15 Male</pre>	1
	Numerator Aggregated Age/Sex: 15+ Male	144
	Numerator Aggregated Age/Sex: <15 Female	0
	Numerator Aggregated Age/Sex: 15+ Female	123
	Denominator Aggregated Age/Sex: <15 Male	1
	Denominator Aggregated Age/Sex: 15+ Male	154
	Denominator Aggregated Age/Sex: <15 Female	0
	Denominator Aggregated Age/Sex: 15+ Female	132
	TX_PVLS_TA Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	n/a
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	977
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical	1,026



record and /or laboratory records in the past 12 months.
Numerator: Age/Sex by Indication: <1 Routine
Numerator: Age/Sex by Indication: <1 Targeted
Numerator: Age/Sex by Indication: 1-9 Routine
Numerator: Age/Sex by Indication: 1-9 Targeted
Numerator: Age/Sex by Indication: 10-14 Female Routine
Numerator: Age/Sex by Indication: 10-14 Female Targeted
Numerator: Age/Sex by Indication: 10-14 Male Routine
Numerator: Age/Sex by Indication: 10-14 Male Targeted
Numerator: Age/Sex by Indication: 15-19 Female Routine
Numerator: Age/Sex by Indication: 15-19 Female Targeted
Numerator: Age/Sex by Indication: 15-19 Male Routine
Numerator: Age/Sex by Indication: 15-19 Male Targeted
Numerator: Age/Sex by Indication: 20-24 Female Routine
Numerator: Age/Sex by Indication: 20-24 Female Targeted
Numerator: Age/Sex by Indication: 20-24 Male Routine
Numerator: Age/Sex by Indication: 20-24 Male Targeted



Numerator: Age/Sex by Indication: 25-49 Female Routine	
Numerator: Age/Sex by Indication:	
25-49 Female Targeted	
Numerator: Age/Sex by Indication:	
25-49 Male Routine	
Numerator: Age/Sex by Indication:	
25-49 Male Targeted	
Numerator: Age/Sex by Indication:	
50+ Female Routine	
Numerator: Age/Sex by Indication: 50+ Female Targeted	
Numerator: Age/Sex by Indication: 50+ Male Routine	
Numerator: Age/Sex by Indication: 50+ Male Targeted	
Numerator: Aggregate Age/Sex by	
Indication: <15 Female Routine	
Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	
Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	
Numerator: Aggregate Age/Sex by	
Indication: <15 Male Targeted	
Numerator: Aggregate Age/Sex by	
Indication: 15+ Female Routine	
Numerator: Aggregate Age/Sex by	
Indication: 15+ Female Targeted	
Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	
Numerator: Aggregate Age/Sex by	
Indication: 15+ Male Targeted	
Numerator: Indication: Routine	977
Numerator: Indication: Targeted	



Numeratory Breg/BE by Indiantions	
Numerator: Preg/BF by Indication:	
Breastfeeding Routine	
Numerator: Preg/BF by Indication:	
Breastfeeding Targeted	
Numerator: Preg/BF by Indication:	
Pregnant Routine	
Numerator: Preg/BF by Indication:	
Pregnant Targeted	
Denominator: Indication: Routine	1,025
Denominator: Indication: Targeted	
Denominator: Age/Sex by	
Indication: <1 Routine	
Denominator: Age/Sex by	
Indication: <1 Targeted	
Denominator: Age/Sex by	
Indication: 1-9 Routine	
Denominator: Age/Sex by	
Indication: 1-9 Targeted	
Denominator: Age/Sex by	
Indication: 10-14 Female Routine	
Denominator: Age/Sex by	
Indication: 10-14 Female Targeted	
Denominator: Age/Sex by	
Indication: 10-14 Male Routine	
Denominator: Age/Sex by	
Indication: 10-14 Male Targeted	
Denominator: Age/Sex by	
Indication: 15-19 Female Routine	
Denominator: Age/Sex by	
Indication: 15-19 Female Targeted	
Denominator: Age/Sex by	
Indication: 15-19 Male Routine	
Denominator: Age/Sex by	
Indication: 15-19 Male Targeted	
indication. To To Male Talyeled	



Denominator: Age/Sex by	
Indication: 20-24 Female Routine	
Denominator: Age/Sex by	
Indication: 20-24 Female Targeted	
Denominator: Age/Sex by	
Indication: 20-24 Male Routine	
Denominator: Age/Sex by	
Indication: 20-24 Male Targeted	
Denominator: Age/Sex by	
Indication: 25-49 Female Routine	
Denominator: Age/Sex by	
Indication: 25-49 Female Targeted	
Denominator: Age/Sex by	
Indication: 25-49 Male Routine	
Denominator: Age/Sex by	
Indication: 25-49 Male Targeted	
Denominator: Age/Sex by	
Indication: 50+ Female Routine	
Denominator: Age/Sex by	
Indication: 50+ Female Targeted	
Denominator: Age/Sex by	
Indication: 50+ Male Routine	
Denominator: Age/Sex by	
Indication: 50+ Male Targeted	
Denominator: Aggregate Age/Sex	
by Indication: <15 Female Routine	
Denominator: Aggregate Age/Sex	
by Indication: <15 Female Targeted	
Denominator: Aggregate Age/Sex	
by Indication: <15 Male Routine	
Denominator: Aggregate Age/Sex	
by Indication: <15 Male Targeted	
Denominator: Aggregate Age/Sex	
by Indication: 15+ Female Routine	



	Denominator: Aggregate Age/Sex	
	by Indication: 15+ Female Targeted	
	Denominator: Aggregate Age/Sex	
	by Indication: 15+ Male Routine	
	Denominator: Aggregate Age/Sex	
	by Indication: 15+ Male Targeted	
	Denominator: Preg/BF by	
	Indication: Breastfeeding Routine	
	Denominator: Preg/BF by	
	Indication: Breastfeeding Targeted	
	Denominator: Preg/BF by	
	Indication: Pregnant Routine	
	Denominator: Preg/BF by	
	Indication: Pregnant Targeted	
	Numerator Aggregated Age/Sex: <15 Male	25
	Numerator Aggregated Age/Sex: 15+ Male	472
	Numerator Aggregated Age/Sex:	24
	<15 Female	
	Numerator Aggregated Age/Sex: 15+ Female	456
	Denominator Aggregated Age/Sex: <15 Male	26
	Denominator Aggregated Age/Sex: 15+ Male	495
	Denominator Aggregated Age/Sex: <15 Female	25
	Denominator Aggregated Age/Sex: 15+ Female	480
	TX_RET_DSD Percent of adults	
TY BET DOD	and children known to be alive and	n/a
TX_RET_DSD	on treatment 12 months after	n/a
	initiation of antiretroviral therapy	



Number of adults and children who	
are still alive and on treatment at	295
12 months after initiating ART	
Total number of adults and children	
who initiated ART in the 12 months	
prior to the beginning of the	
reporting period, including those	330
who have died, those who have	
stopped ART, and those lost to	
follow-up	
Age/Sex: <1 (Numerator: Number	
of adults and children who are still	
alive and on treatment at 12	
months after initiating ART	
Age/Sex: 1-9 (Numerator: Number	
of adults and children who are still	
alive and on treatment at 12	
months after initiating ART	
Age/Sex: 10-14 Male (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART	
Age/Sex: 15-19 Male (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART	
Age/Sed: 20-24 Male (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART	
Age/Sex: 25-49 Male (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART	
Age/Sex: 50+ Male (Numerator:	
0	



Number of adults and children who
are still alive and on treatment at
12 months after initiating ART
Age/Sex: 10-14 Female
(Numerator: Number of adults and
children who are still alive and on
treatment at 12 months after
initiating ART
Age/Sex: 15-19 Female
(Numerator: Number of adults and
children who are still alive and on
treatment at 12 months after
initiating ART
Age/Sex: 20-24 Female
(Numerator: Number of adults and
children who are still alive and on
treatment at 12 months after
initiating ART
Age/Sex: 25-49 Female
(Numerator: Number of adults and
children who are still alive and on
treatment at 12 months after
initiating ART
Age/Sex: 50+ Female (Numerator:
Number of adults and children who
are still alive and on treatment at
12 months after initiating ART
Age/Sex: >1 (Denominator: Total
number of adults and children who
initiated ART in the 12 months prior
to the beginning of the reporting
period, including those who have
died, those who have stopped
ART, and those lost to follow-up)
Age/Sex: 1-9 (Denominator: Total
number of adults and children who
• •



l I	
initiated ART in the 12 months prior	
to the beginning of the reporting	
period, including those who have	
died, those who have stopped	
ART, and those lost to follow-up)	
Age/Sex: 10-14 Male	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Age/Sex: 15-19 Male	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Age/Sex: 20-24 Male	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Age/Sex: 25-49 Male	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	



those lost to follow-up)
Age/Sex: 50+ Male (Denominator:
Total number of adults and children
who initiated ART in the 12 months
prior to the beginning of the
reporting period, including those
who have died, those who have
stopped ART, and those lost to
follow-up)
Age/Sex: 10-14 Female
(Denominator: Total number of
adults and children who initiated
ART in the 12 months prior to the
beginning of the reporting period,
including those who have died,
those who have stopped ART, and
those lost to follow-up)
Age/Sex: 15-19 Female
(Denominator: Total number of
adults and children who initiated
ART in the 12 months prior to the
beginning of the reporting period,
including those who have died,
those who have stopped ART, and
those lost to follow-up)
Age/Sex: 20-24 Female
(Denominator: Total number of
adults and children who initiated
ART in the 12 months prior to the
beginning of the reporting period,
including those who have died,
those who have stopped ART, and
those lost to follow-up)
Age/Sex: 25-49 Female
(Denominator: Total number of
` adults and children who initiated



ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Age/Sex: 50+ Female	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Aggregated Age: <15 (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART)	
Aggregated Age: 15+ (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART)	
Aggregated Age: <15	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Aggregated Age: 15+	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
in the second se	



those lost to follow-up)	
Numerator by Status: Pregnant	
Numerator by Status:	
Breastfeeding	
Denominator by Status: Pregnant	
Denominator by Status:	
Breastfeeding	
Aggregated Age/Sex: <15 Male	
(Numerator: Number of adults and	
children who are still alive and on	1
treatment at 12 months after	
initiating ART)	
Aggregated Age/Sex: 15+ Male	
(Numerator: Number of adults and	
children who are still alive and on	156
treatment at 12 months after	
initiating ART)	
Aggregated Age/Sex: <15 Female	
(Numerator: Number of adults and	
children who are still alive and on	0
treatment at 12 months after	
initiating ART)	
Aggregated Age/Sex: 15+ Female	
(Numerator: Number of adults and	
children who are still alive and on	138
treatment at 12 months after	
initiating ART)	
Aggregated Age/Sex: <15 Male	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	1
beginning of the reporting period,	1
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	



Aggregated Age/Sex: 15+ Male	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	177
beginning of the reporting period,	177
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Aggregated Age/Sex: <15 Female	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	0
beginning of the reporting period,	0
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Aggregated Age/Sex: 15+ Female	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	152
beginning of the reporting period,	152
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
TX_RET_TA Percent of adults and	
children known to be alive and on	2/2
treatment 12 months after initiation	n/a
of antiretroviral therapy	
Number of adults and children who	
are still alive and on treatment at	493
12 months after initiating ART	
Total number of adults and children	
who initiated ART in the 12 months	
prior to the beginning of the	548
reporting period, including those	
who have died, those who have	
	 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have stopped ART, and those lost to follow-up) Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have stopped ART, and those lost to follow-up) Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) TX_RET_TA Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy Number of adults and children who are still alive and on treatment at 12 months after initiating ART Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting periot, including those who have stopped ART, and those lost to follow-up)



stopped ART, and those lost to
follow-up
Age/Sex: <1 (Numerator: Number
of adults and children who are still
alive and on treatment at 12
months after initiating ART)
Age/Sex: 1-9 (Numerator: Number
of adults and children who are still
alive and on treatment at 12
months after initiating ART)
Age/Sex: 10-14 Male (Numerator:
Number of adults and children who
are still alive and on treatment at
12 months after initiating ART)
Age/Sex: 15-19 Male (Numerator:
Number of adults and children who
are still alive and on treatment at
12 months after initiating ART)
Age/Sex: 20-24 Male (Numerator:
Number of adults and children who
are still alive and on treatment at
12 months after initiating ART)
Age/Sex: 25-49 Male (Numerator:
Number of adults and children who
are still alive and on treatment at
12 months after initiating ART)
Age/Sex: 50+ Male (Numerator:
Number of adults and children who
are still alive and on treatment at
12 months after initiating ART)
Age/Sex: 10-14 Female
(Numerator: Number of adults and
children who are still alive and on
treatment at 12 months after
initiating ART)
· · ·



Age/Sex: 15-19 Female
(Numerator: Number of adults and
children who are still alive and on
treatment at 12 months after
initiating ART)
Age/Sex: 20-24 Female
(Numerator: Number of adults and
children who are still alive and on
treatment at 12 months after
initiating ART)
Age/Sex: 25-49 Female
(Numerator: Number of adults and
children who are still alive and on
treatment at 12 months after
initiating ART)
Age/Sex: 50+ Female (Numerator:
Number of adults and children who
are still alive and on treatment at
12 months after initiating ART)
Age/Sex: <1 (Denominator: Total
number of adults and children who
initiated ART in the 12 months prior
to the beginning of the reporting
period, including those who have
died, those who have stopped
ART, and those lost to follow-up)
Age/Sex: 1-9 (Denominator: Total
number of adults and children who
initiated ART in the 12 months prior
to the beginning of the reporting
period, including those who have
died, those who have stopped
ART, and those lost to follow-up)
Age/Sex: 10-14 Male
(Denominator: Total number of
adults and children who initiated



ART in the 12 months prior to the beginning of the reporting period, including those who have stopped ART, and those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to	
including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 51-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	ART in the 12 months prior to the
those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	beginning of the reporting period,
tose lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those lost to follow-up) Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have stopped ART, and those lost to follow-up) Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those lost to follow-up) Age/Sex: 50+ Male (Denominator: Total number of adults and	including those who have died,
Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those lost to follow-up) Age/Sex: 25-49 Male (Denominator: Total number of adults and children who ave died, those lost to follow-up) Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have stopped ART, and those who have stopped ART, and those lost to follow-up) Age/Sex: 50+ Male (Denominator: Total number of adults and children who have stopped ART, and those lost to follow-up) Age/Sex: 50+ Male (Denominator:	those who have stopped ART, and
(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	those lost to follow-up)
adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	Age/Sex: 15-19 Male
ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 55-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have stopped ART, and those lost to follow-up) Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	(Denominator: Total number of
beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	adults and children who initiated
including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	ART in the 12 months prior to the
those who have stopped ART, and those lost to follow-up) Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	beginning of the reporting period,
those lost to follow-up) Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	including those who have died,
Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those lost to follow-up) Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART, and those lost to follow-up) Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those	those who have stopped ART, and
(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	those lost to follow-up)
adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	Age/Sex: 20-24 Male
ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	(Denominator: Total number of
beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	adults and children who initiated
including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	ART in the 12 months prior to the
those who have stopped ART, and those lost to follow-up) Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	beginning of the reporting period,
those lost to follow-up) Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	including those who have died,
Age/Sex: 25-49 Male(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	those who have stopped ART, and
(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	those lost to follow-up)
adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	Age/Sex: 25-49 Male
ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	(Denominator: Total number of
beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	adults and children who initiated
including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	ART in the 12 months prior to the
those who have stopped ART, and those lost to follow-up) Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	beginning of the reporting period,
those lost to follow-up) Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	including those who have died,
Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	those who have stopped ART, and
Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	those lost to follow-up)
who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	Age/Sex: 50+ Male (Denominator:
prior to the beginning of the reporting period, including those who have died, those who have	Total number of adults and children
reporting period, including those who have died, those who have	who initiated ART in the 12 months
who have died, those who have	prior to the beginning of the
	reporting period, including those
stopped ART, and those lost to	who have died, those who have
	stopped ART, and those lost to



follow-up)
Age/Sex: 10-14 Female
(Denominator: Total number of
` adults and children who initiated
ART in the 12 months prior to the
beginning of the reporting period,
including those who have died,
those who have stopped ART, and
those lost to follow-up)
Age/Sex: 15-19 Female
(Denominator: Total number of
adults and children who initiated
ART in the 12 months prior to the
beginning of the reporting period,
including those who have died,
those who have stopped ART, and
those lost to follow-up)
Age/Sex: 20-24 Female
(Denominator: Total number of
adults and children who initiated
ART in the 12 months prior to the
beginning of the reporting period,
including those who have died,
those who have stopped ART, and
those lost to follow-up)
Age/Sex: 25-49 Female
(Denominator: Total number of
adults and children who initiated
ART in the 12 months prior to the
beginning of the reporting period,
including those who have died,
those who have stopped ART, and
those lost to follow-up)
Age/Sex: 50+ Female
(Denominator: Total number of
adults and children who initiated



ART in the 12 months prior to the
beginning of the reporting period,
including those who have died,
those who have stopped ART, and
those lost to follow-up)
Aggregated Age: <15 (Numerator:
Number of adults and children who
are still alive and on treatment at
12 months after initiating ART)
Aggregated Age: 15+ (Numerator:
Number of adults and children who
are still alive and on treatment at
12 months after initiating ART)
Aggregated Age: <15
(Denominator: Total number of
adults and children who initiated
ART in the 12 months prior to the
beginning of the reporting period,
including those who have died,
those who have stopped ART, and
those lost to follow-up)
Aggregated Age: 15+
(Denominator: Total number of
adults and children who initiated
ART in the 12 months prior to the
beginning of the reporting period,
including those who have died,
those who have stopped ART, and
those lost to follow-up)
Numerator by Status: Pregnant
Numerator by Status:
Breastfeeding
Denominator by Status: Pregnant
Denominator by Status:
Breastfeeding



Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	15
Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	200
Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	17
Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	261
Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	17
Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	222



		I
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	19
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	290
LAB_PT_TA	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	
	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	15
	CD4: Number of laboratories that participate in this PT program	16
	CD4: Number of laboratories that perform this testing	
	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	
	Early infant diagnostics: Number of laboratories that participate in this PT program	



Early infant diagnostics: Number of	
laboratories that perform this	
testing	
HIV serologic/diagnostic testing:	
Number of laboratories that	95
achieve acceptable successful	90
passing criteria in this PT program	
HIV serologic/diagnostic testing:	
Number of laboratories that	112
participate in this PT program	
HIV serologic/diagnostic testing:	
Number of laboratories that	
perform this testing	
HIV viral load: Number of	
laboratories that achieve	10
acceptable successful passing	12
criteria in this PT program	
HIV viral load: Number of	
laboratories that participate in this	12
PT program	
HIV viral load: Number of	
laboratories that perform this	
testing	
TB diagnostics (AFB microscopy):	
Number of laboratories that	
achieve acceptable successful	
passing criteria in this PT program	
TB diagnostics (AFB microscopy):	
Number of laboratories that	
participate in this PT program	
TB diagnostics (AFB microscopy):	
Number of laboratories that	
perform this testing	
TB diagnostics (Xpert MTB/RIF):	
Number of laboratories that	



	achieve acceptable successful	
	passing criteria in this PT program	
	TB diagnostics (Xpert MTB/RIF):	
	Number of laboratories that	
	participate in this PT program	
	TB diagnostics (Xpert MTB/RIF):	
	Number of laboratories that	
	perform this testing	
	TB diagnostics (Culture/DST):	
	Number of laboratories that	
	achieve acceptable successful	
	passing criteria in this PT program	
	TB diagnostics (Culture/DST):	
	Number of laboratories that	
	participate in this PT program	
	TB diagnostics (Culture/DST):	
	Number of laboratories that	
	perform this testing	
	Number of new HCW who	
	graduated from a pre-service	
	training institution or program as a	415
	result of PEPFAR-supported	415
	strengthening efforts, within the	
	reporting period, by select cadre	
	By Graduates: Doctors	
HRH PRE	By Graduates: Nurses	
	By Graduates: Midwives	
	By Graduates: Social service	
	workers	
	By Graduates: Laboratory	
	professionals	
	By Graduates: Other	
	Sum of Graduates disaggreagtes	
	Curr of Claudales disayyreayles	



Partners and Implementing Mechanisms

Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
16576	AIDS Care China	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	300,000
16622	Chinese Center for Disease Prevention and Control	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GAP, GHP-State	1,300,000
17035	TBD	TBD	Redacted	Redacted	Redacted
17084	U.S. Department of Defense (Defense)	Other USG Agency	U.S. Department of Defense	GHP-State	0
17092	World Health Organization	Multi-lateral Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	75,000
17309	FHI 360	NGO	U.S. Agency for International Development	GHP-USAID	3,727,521



17815	Research Triangle International	Private Contractor	U.S. Agency for International Development	GHP-USAID	0
17842	Health Research Inc./New York State Department of Health	Other USG	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	50,000
17858	твр	ТВD	Redacted	Redacted	Redacted
17859	твр	твр	Redacted	Redacted	Redacted
17860	TBD	твр	Redacted	Redacted	Redacted
18448	TBD	TBD	Redacted	Redacted	Redacted
18450	TBD	ТВD	Redacted	Redacted	Redacted



Implementing Mechanism(s)

Implementing Mechanism Details

Mechanism ID: 16576	Mechanism Name: Engaging Local NGOs
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: AIDS Care China	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount	
China	0	

Total All Funding Sources: 300,000		
Applied Pipeline Amount: 0		
Total All Funding Sources and A		
Managing Country	Funding Source	Funding Amount
China	GHP-State	300,000

Cross-Cutting Budget Attribution(s)

Human Resources for Health 265,386

Budget Code Information

Mechanism ID:	16576		
Mechanism Name:	Engaging Local NGOs		
Prime Partner Name:	AIDS Care China		
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HBHC	172,435	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	42,639	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	18,979	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	65,947	0

Implementing Mechanism Indicator Information

OU	Indicator Number	Label	2017
China	HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,618
China	HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	18
China	HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	834
China	HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	24
China	HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	742
China	HTC_TST_DSD	Sum of Aggregated Age/Sex <15	42
China	HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	1,576
China	HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	1,618
China	HTC_TST_DSD	D Test Result by Aggregated Age and Sex: Positive <15 Male	
China	HTC_TST_DSD	Test Result by Aggregated Age and Sex:	398



		Positive 15+ Male	
China	HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	5
China	HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	196
China	HTC_TST_DSD	Service Delivery Point (Community): Index testing	635
China	HTC_TST_DSD	Service Delivery Point (Community): Homebased testing	0
China	HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	0
China	HTC_TST_DSD	Service Delivery Point (Community): Other	933
China	HTC_TST_DSD	Service Delivery Point (Facility): VCT	35
China	HTC_TST_DSD	Service Delivery Point (Facility): Index testing	15
China	TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	390
China	TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1
China	TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	219
China	TX_CURR_DSD	Aggregated Age/Sex: <15 Female	0
China	TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	170
China	TX_CURR_DSD	Sum of Aggregated Age/Sex <15	1
China	TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	389
China	TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	390
China	TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	60
China	TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	0
China	TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	42
China	TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	0
China	TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+	18



		Female	
China	TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	60
China	TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	268
China	TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	287
China	TX_PVLS_DSD	Numerator: Indication: Routine	268
China	TX_PVLS_DSD	Numerator: Indication: Targeted	0
China	TX_PVLS_DSD	Denominator: Indication: Routine	287
China	TX_PVLS_DSD	Denominator: Indication: Targeted	0
China	TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	1
China	TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	144
China	TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	0
China	TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	123
China	TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	1
China	TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	154
China	TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	0
China	TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	132
China	TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	295
China	TX_RET_DSD	Total number of adults and children who	330



		1	
		initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	
China	TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1
China	TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	156
China	TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
China	TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	138
China	TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1
China	TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	177
China	TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and	0



		children who initiated ART in the 12 months prior to the beginning of the reporting	
		period, including those who have died,	
		those who have stopped ART, and those	
		lost to follow-up)	
		Aggregated Age/Sex: 15+ Female	
		(Denominator: Total number of adults and	
		children who initiated ART in the 12 months	
China	TX_RET_DSD	prior to the beginning of the reporting	152
		period, including those who have died,	
		those who have stopped ART, and those	
		lost to follow-up)	

Mechanism ID: 16622	Mechanism Name: China CDC COAG		
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement		
Prime Partner Name: Chinese Center for Disease Prevention and Control			
Agreement Start Date: Redacted Agreement End Date: Redacted			
TBD: No New Mechanism: No			
G2G: Yes	Managing Agency: HHS/CDC		

Benefiting Country	Benefiting Country Planned Amount
China	0

Total All Funding Sources: 1,300,000		
Applied Pipeline Amount: 0		
Total All Funding Sources ar	nd Applied Pipeline Amount:	
1,300,000		
Managing Country	Funding Source	Funding Amount
China	GAP	150,000
China	GHP-State	1,150,000



Cross-Cutting Budget Attribution(s)

Human Resources for Health	175,000
Key Populations: MSM and TG	610,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Focus Area:	Monitoring and evaluation of MSM/TG programs

Budget Code Information

	16622 China CDC COAG Chinese Center for Disease Prevention and Control		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	133,588	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	160,088	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	HVSI	202,677	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	146,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	166,857	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	361,790	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	МТСТ	5,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	124,000	0

Implementing Mechanism Indicator Information

OU	Indicator Number	Label	2017
China	KP_PREV_TA	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	20,371
China	KP_PREV_TA	Total estimated number of key population in the catchment area	138,571
China	KP_PREV_TA	By key population type: Men who have sex	20,371



r	1		
		with men and are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
China	KP_PREV_TA	By key population type: Men who have sex with men and are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	138,571
China	HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	11,900
China	HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	11,900
China	HTC_TST_TA	Sum of Aggregated Age/Sex 15+	11,900
China	HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	11,900
China	HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	962
China	HTC_TST_TA	Service Delivery Point (Community): Index testing	11,900

Mechanism ID: 17035	TBD: Yes	
REDACTED		

Mechanism ID: 17084	Mechanism Name: U.S. DoD, Laos	
Funding Agency: DOD	Procurement Type: Grant	
Prime Partner Name: U.S. Department of Defense (Defense)		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
G2G: No	Managing Agency:	



Benefiting Country		Benefiting Country Planned Amount	
Laos			
Total All Funding Sources:	D		
Applied Pipeline Amount: 20	D,000		
Total All Funding Sources a	nd Applied Pipeline Am	nount: 20,000	
Managing Country	Funding Source	Funding Amount	
Laos	GHP-State	0	

(No data provided.)

Budget Code Information

Mechanism ID: Mechanism Name: Prime Partner Name:			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HMBL	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17092	Mechanism Name: World Health Organization	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: World Health Organization		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
G2G: No	Managing Agency:	

Benefiting Country		Benefiting Country Planned Amount	
Laos		0	

Total All Funding Sources: 75,000		
Applied Pipeline Amount: 0		
Total All Funding Sources and A		
Managing Country	Funding Source	Funding Amount
Thailand	GHP-State	75,000

Cross-Cutting Budget Attribution(s)



Key Populations: MSM and TG	20,000	
Focus Area:	Implementation of core HIV prevention interventions	
	for MSM/TG that are consistent with the current	
	PEPFAR technical guidance	
Focus Area: Collection and use of strategic information		
Focus Area:	Monitoring and evaluation of MSM/TG programs	

Budget Code Information

Mechanism ID: 17092				
Mechanism Name:	World Health Organization			
Prime Partner Name:	World Health Organizat	World Health Organization		
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Care	HVTB	5,400	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Governance and Systems	HLAB	24,150	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Governance and Systems	OHSS	33,200	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Prevention	HVCT	12,250	0	

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details



Mechanism ID: 17309	Mechanism Name: LINKAGES
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount
Laos	873,225
Thailand	2,854,296

Total All Funding Sources 3,727,521	:	
Applied Pipeline Amount:	1,250,000	
Total All Funding Sources		
4,977,521		
Managing Country	Funding Source	Funding Amount
Laos	GHP-USAID	873,225
Thailand	GHP-USAID	2,854,296

Key Populations: MSM and TG	3,727,521
Focus Area:	Training of health workers and community outreach
	workers
Focus Area:	Implementation of core HIV prevention interventions
	for MSM/TG that are consistent with the current
	PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and
	operational research among MSM/TG and their sex
	partners



Focus Area:	Monitoring and evaluation of MSM/TG programs	
Focus Area:	Procurement of condoms, lubricants, and other	
	commodities essential to core HIV services for	
	MSM/TG	

Budget Code Information

Mechanism ID:	17309		
Mechanism Name: LINKAGES			
Prime Partner Name:	FHI 360		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	631,088	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	1,526	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	413,070	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	890,821	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	795,913	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	995,103	0

Implementing Mechanism Indicator Information



OU	Indicator Number	Label	2017
Laos	KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	4,020
Laos	HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,024
Laos	HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,024
Laos	HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	1,024
Laos	HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	1,024
Laos	HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	72
Laos	HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	2,388
Laos	HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	2,388
Laos	HTC_TST_TA	Sum of Aggregated Age/Sex 15+	2,388
Laos	HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	2,388
Laos	HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	0
Laos	TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	102
Laos	TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	69
Laos	HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting	185



		period, by select cadre	
Thailand	PrEP_NEW_DSD	Number of individuals who have received antiretroviral preexposure	750
Thailand	KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	20,140
Thailand	HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	15,000
Thailand	HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	15,000
Thailand	HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	15,000
Thailand	HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	15,000
Thailand	HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	2,581
Thailand	TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	3,900
Thailand	TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,284
Thailand	HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	230

Mechanism ID: 17815	Mechanism Name: Inform Asia: USAID"s Health Research Program, Associate Award	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Research Triangle International		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	



G2G: No	Managing Agency:

Total All Funding Sources: 0		
Applied Pipeline Amount: 279,50		
Total All Funding Sources and Applied Pipeline Amount: 279,500		
Managing Country	Funding Source	Funding Amount
Thailand	GHP-USAID	0

(No data provided.)

Budget Code Information

Mechanism ID: Mechanism Name:	17815 Inform Asia: USAID"s Health Research Program, Associate Award		
Prime Partner Name:	Research Triangle International		
Strategic Area	Budget Code Planned Amount On Hold Amount		
Governance and Systems	OHSS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Mechanism ID: 17842	Mechanism Name: Quality Improvement Center for Impact (QICI)		
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement		
Prime Partner Name: Health Research Inc./New Yor	k State Department of Health		
Agreement Start Date: Redacted	Agreement End Date: Redacted		



TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Benefiting Country	Benefiting Country Planned Amount			
Laos	0			
Thailand	0			

Total All Funding Sources: 50,000		
Applied Pipeline Amount: 0		
Total All Funding Sources and A		
Managing Country	Funding Amount	
Thailand	50,000	

(No data provided.)

Budget Code Information

Mechanism ID:	17842				
Mechanism Name:	Quality Improvement Center for Impact (QICI)				
Prime Partner Name:	Health Research Inc./New York State Department of Health				
Strategic Area	Budget Code Planned Amount On Hold Amount				
Care	HBHC	50,000	0		

Implementing Mechanism Indicator Information

(No data provided.)



Mechanism ID: 17858	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17859	TBD: Yes	
REDACTED		

Implementing Mechanism Details

Mechanism ID: 17860	TBD: Yes	
REDACTED		

Implementing Mechanism Details

Mechanism ID: 18448	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18450	TBD: Yes
REDACTED	

Agency Information - Costs of Doing Business U.S. Agency for International Development

Agency Cost						Total All Cost of
of Doing	GAP	GHP-State	GHP-USAID	Applied	Total	Doing
•	GAP	GHF-State	GHF-03AID	Pipeline	Total	Business
Business						Categories
						and Applied



						Pipeline Amount
Computers/IT Services			15,554	22,981	15,554	38,535
ICASS			15,836	5,804	15,836	21,640
Management Meetings/Profes sional Development			38,614	886	38,614	39,500
Non-ICASS Administrative Costs			119,639	2,666	119,639	122,305
Staff Program Travel			66,041	5,759	66,041	71,800
USG Staff Salaries and Benefits - Internationally Recruited			233,268	99,201	233,268	332,469
USG Staff Salaries and Benefits - Locally Recruited			236,933	113,593	236,933	350,526
Total	0	0	725,885	250,890	725,885	976,775

U.S. Department of Defense

						Total All
Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	HP-USAID Pipeline	Total	Cost of
						Doing
						Business
						Categories
						and Applied



						Pipeline Amount
Computers/IT Services		0		1,246	0	1,246
ICASS		0		37,683	0	37,683
Management Meetings/Profes sional Development		0		785	0	785
Staff Program Travel		0		2,012	0	2,012
USG Staff Salaries and Benefits - Internationally Recruited				0	0	0
USG Staff Salaries and Benefits - Locally Recruited				9,682	0	9,682
Total	0	0	0	51,408	0	51,408

U.S. Department of Health and Human Services/Centers for Disease Control and Prevention

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
-------------------------------------	-----	-----------	-----------	---------------------	-------	--



Total	3,966,875	2,607,921	0	0	6,574,796	6,574,796
Recruited						
Locally						
Benefits -	2,408,275	0		0	2,408,275	2,408,275
Salaries and						
USG Staff						
Recruited						
Internationally						
Benefits -	371,600	983,125		0	1,354,725	1,354,725
Salaries and						
USG Staff						
Travel	345,000	155,000		0	500,000	500,000
Staff Program	245.000	155 000		~	E00.000	E00.000
Costs						
Administrative	545,000	829,796		0	1,374,796	1,374,796
Non-ICASS						
Development						
sional	60,000	60,000		0	120,000	120,000
Meetings/Profes						
Management						
Institutional Contractors	102,000	350,000		0	452,000	452,000
ICASS	100,000	215,000		0	315,000	315,000
	400.000	245 000		0	245 000	245 000
Computers/IT Services	35,000	15,000		0	50,000	50,000